Chronic obstructive pulmonary disease (COPD)

Straight to the point of care
# Table of Contents

## Overview
- Summary .................................................. 3
- Definition ............................................... 3

## Theory
- Epidemiology ............................................. 4
- Aetiology ................................................ 4
- Pathophysiology ........................................ 4
- Case history ............................................ 5

## Diagnosis
- Approach ............................................... 7
- History and exam ..................................... 9
- Risk factors ............................................ 11
- Investigations ......................................... 13
- Differentials ........................................... 18
- Criteria .................................................. 19
- Screening ............................................... 20

## Management
- Approach ............................................... 21
- Treatment algorithm overview ..................... 36
- Treatment algorithm ................................ 39
- Emerging ............................................... 74
- Primary prevention .................................... 75
- Secondary prevention ................................. 75
- Patient discussions ................................... 75

## Follow up
- Monitoring ............................................... 78
- Complications ......................................... 79
- Prognosis ................................................ 81

## Guidelines
- Diagnostic guidelines ................................ 82
- Treatment guidelines ................................. 82

## Online resources

## Evidence tables

## References

## Images

## Disclaimer
Chronic obstructive pulmonary disease (COPD)

Overview

Summary

Chronic obstructive pulmonary disease (COPD) is a progressive disease state characterised by airflow limitation that is not fully reversible.

Suspected in patients with a history of smoking, occupational and environmental risk factors, or a personal or family history of chronic lung disease.

Presents with progressive shortness of breath, wheeze, cough, and sputum production.

Diagnostic tests include pulmonary function tests, chest x-ray, chest computed tomography scan, oximetry, and arterial blood gas analysis.

Patients should be encouraged to stop smoking or occupational exposure and be vaccinated against viral influenza and *Streptococcus pneumoniae*.

Treatment options include bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, antibiotics, and mucolytics.

Long-term oxygen therapy improves survival in severe COPD.

Pulmonary rehabilitation improves exercise tolerance, dyspnoea, and health status in stable patients.

Definition

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterised by airflow limitation that is not fully reversible. It encompasses both emphysema and chronic bronchitis. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases. It is primarily caused by cigarette smoking. Although COPD affects the lungs, it also has significant systemic consequences. Exacerbations and comorbidities are important contributors to the overall condition and prognosis in individual patients.[1]

[BMJ talk medicine podcast: a clinical guide to COPD](https://soundcloud.com/bmjpodcasts/a-clinical-guide-to-copd-with-prof-mike-morgan)
Epidemiology

COPD is more common in older people, especially those aged 65 years and older. COPD prevalence is highest in the World Health Organization region of the Americas and lowest in the South-East Asia and Western Pacific regions. The pooled global prevalence is 15.7% in men and 9.93% in women.[9] The prevalence of COPD in the US is estimated at 14%.[10] A 2019 National Health Interview Survey revealed that the prevalence of COPD in US adults was greater in those living in non-metropolitan areas than in metropolitan areas, at 8.0% and 4.0%, respectively.[11] Prevalence of COPD increased with age regardless of urbanisation level.

Globally, deaths from COPD increased by 23% from 1990 to 2017, and currently there are about 3 million deaths from COPD each year.[12] The expanding epidemic of smoking and ageing of the world population, as well as the reduced mortality from other causes of death such as cardiovascular disease, mean that by 2060 there may be over 5.4 million deaths per year due to COPD and related diseases.[1]

Previously, most studies reported that the prevalence and mortality of COPD are greater in men than women.[12] However, data from 2012 to 2013 from developed countries suggest that COPD prevalence is now almost equal in men and women, probably due to different patterns of cigarette smoking.[13] Some studies have also suggested that women may have a greater risk of airflow obstruction than men despite exposure to a similar dose of tobacco.[14]

An international study reported that the prevalence of COPD in never-smokers is 12.2%.[15] This may be due to air pollution or indoor burning of solid fuels in low and middle income countries. In the US, the prevalence of COPD in never-smokers is 2.2%. Many of these cases are attributed to workplace exposures.[16]

Aetiology

Tobacco smoking is by far the main risk factor for COPD. It is responsible for 40% to 70% of COPD cases and exerts its effect by causing an inflammatory response, cilia dysfunction, and oxidative injury.[17] Air pollution, indoor burning of biomass fuels, and occupational exposure to dusts, chemical agents, and fumes are other aetiologies.[18] [19] [20] Inhalation of high doses of pesticides is linked to increased incidence of COPD, as are high levels of particulate matter.[21] [22] [23] [24] Oxidative stress and an imbalance in proteases and antiproteases are also important factors in the pathogenesis of COPD, especially in patients with alpha-1 antitrypsin deficiency.[25] The risk of developing COPD can be increased by processes that affect optimal lung growth and therefore lung function.[26] These processes may go back as far as gestation, birth, childhood, and adolescence. For example, there is a positive association between birthweight and FEV1 in adulthood. Disadvantageous factors in childhood may be as important as heavy smoking in predicting lung function in adulthood.[27]

Pathophysiology

The hallmark of COPD is chronic inflammation that affects central and peripheral airways, lung parenchyma and alveoli, and pulmonary vasculature. Repeated injury and repair leads to structural and physiological changes. The inflammatory and structural changes in the lung increase with disease severity and persist after smoking cessation.[25]
Chronic obstructive pulmonary disease (COPD)

**Theory**

The main components of these changes are narrowing and remodelling of airways, increased number of goblet cells, enlargement of mucus-secreting glands of the central airways, alveolar loss, and, finally, vascular bed changes leading to pulmonary hypertension.

Evidence suggests that the host response to inhaled stimuli generates the inflammatory reaction responsible for the changes in the airways, alveoli, and pulmonary blood vessels. Activated macrophages, neutrophils, and leukocytes are the core cells in this process. Oxidative stress and an excess of proteases amplify the effects of chronic inflammation. Airway remodelling thickens the epithelium, lamina propria, smooth muscle, and adventitia of airways less than 2 mm in diameter, leading to progressive loss of patent terminal and transitional bronchioles.[25] Growing evidence implicates eosinophils, a leukocyte usually involved in allergic disease, in the COPD inflammatory cascade.[28]

Elastin breakdown and subsequent loss of alveolar integrity causes emphysema.[29] Ciliary dysfunction and increased goblet cell size and number lead to excessive mucus secretion.

Increased airway resistance is the physiological definition of COPD. Decreased elastic recoil, fibrotic changes in lung parenchyma, and luminal obstruction of airways by secretions all contribute to increased airways resistance. Expiratory flow limitation promotes hyperinflation. Hyperinflation and destruction of lung parenchyma predispose patients with COPD to hypoxia, particularly during activity. Progressive hypoxia causes vascular smooth muscle thickening with subsequent pulmonary hypertension, which is a late development conveying a poor prognosis.[30] [31] Reduced gas transfer may also lead to hypercapnia as the disease progresses.

Systemic inflammatory mediators may contribute to skeletal muscle wasting or cachexia, and initiate or worsen cardiac, metabolic, and skeletal comorbidities.[1] [6]

**Case history**

**Case history #1**

A 66-year-old man with a smoking history of one pack per day for the past 47 years presents with progressive shortness of breath and chronic cough, productive of yellowish sputum, for the past 2 years. On examination he appears cachectic and in moderate respiratory distress, especially after walking to the examination room, and has pursed-lip breathing. His neck veins are mildly distended. Lung examination reveals a barrel chest and poor air entry bilaterally, with moderate inspiratory and expiratory wheezing. Heart and abdominal examination are within normal limits. Lower extremities exhibit scant pitting oedema.

**Case history #2**

A 56-year-old woman with a history of smoking presents to her primary care physician with shortness of breath and cough for several days. Her symptoms began 3 days ago with rhinorrhoea. She reports a chronic morning cough productive of white sputum, which has increased over the past 2 days. She has had similar episodes each winter for the past 4 years. She has smoked 1 to 2 packs of cigarettes per day for 40 years and continues to smoke. She denies haemoptysis, chills, or weight loss and has not received any relief from over-the-counter cough preparations.
**Other presentations**

Some patients report chest tightness, which often follows exertion and may arise from intercostal muscle contraction. Fatigue, weight loss, muscle loss, and anorexia are common in patients with severe and very severe COPD.[1] Other presentations include weight loss, haemoptysis, cyanosis, and morning headaches secondary to hypercapnia. Chest pain and haemoptysis are uncommon symptoms of COPD and raise the possibility of alternative diagnoses.[2]

Physical examination may demonstrate hypoxia, use of accessory muscles, paradoxical rib movements, distant heart sounds, lower-extremity oedema and hepatomegaly secondary to cor pulmonale, and asterixis secondary to hypercapnia.

Patients may also present with signs and symptoms of COPD complications. These include severe shortness of breath, severely decreased air entry, and chest pain secondary to an acute COPD exacerbation or spontaneous pneumothorax.[3][4] Patients with COPD often have other comorbidities, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome and diabetes, osteoporosis, depression, anxiety, lung cancer, gastro-oesophageal reflux disease, bronchiectasis, obstructive sleep apnoea, and cognitive impairment.[5][6][1] A UK study found that 14.5% of patients with COPD had a concomitant diagnosis of asthma, whereas a global meta-analysis estimated the pooled prevalence of asthma in patients with COPD to be 29.6% (range: 12.6% to 55.5%).[7][8]
**Approach**

For updates on diagnosis and management of coexisting conditions during the coronavirus disease 2019 (COVID-19) pandemic, see our topic ‘Management of coexisting conditions in the context of COVID-19’.

**History**

COPD has an insidious onset and usually presents in older people. A history of productive cough, wheezing, and shortness of breath, particularly with exercise, is typical. Other symptoms include frequent bronchitis, reduced exercise tolerance, waking at night with breathlessness, ankle swelling, and fatigue.[2]

Patients may complain of fatigue as a result of disrupted sleep secondary to constant nocturnal cough and persistent hypoxia and hypercapnia. The patient's smoking history, occupational exposures, comorbidities, and any family history of lung disease should be determined. A history of previous exacerbations and hospitalisations should be sought.

Patients with COPD may also present with acute, severe shortness of breath, fever, and chest pain during acute infectious exacerbation. See our topic on ‘Acute exacerbation of chronic obstructive pulmonary disease’ for further information.

**Physical examination**

Although spirometry is required to make the diagnosis, a physical examination is an important part of patient care.[1] Examination may show tachypnoea, respiratory distress, use of accessory muscles, and intercostal retraction. Barrel chest is a common observation. There may be hyper-resonance on percussion, and distant breath sounds and poor air movement on auscultation. Wheezing, coarse crackles, clubbing, and cyanosis, as well as signs of right-sided heart failure (distended neck veins, loud P2, hepatomegaly, hepatojugular reflux, and lower-extremity oedema), may be present. Occasionally patients may exhibit asterixis - loss of postural control in the outstretched arms (commonly known as a flap) caused by hypercapnia. This is due to impaired gas exchange in lung parenchyma, worsens with exercise, and is suggestive of respiratory failure.

**Initial tests**

Spirometry is required to make the diagnosis of COPD and is also used for monitoring disease progress.[1] [2] [46] It is the most reproducible and objective measure of airflow limitation. Spirometry should be performed after administering an adequate dose of at least one short-acting inhaled bronchodilator to minimise variability.[1] Patients with COPD have a distinctive pattern seen on spirometry, with a reduced FEV1 and FEV1/FVC ratio. The presence of airflow limitation is defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria as a post-bronchodilator FEV1/FVC <0.70.[1] In cases where FVC may be hard to measure, forced expiratory volume at 6 seconds (FEV6) can be used.[47] Spirometry also indicates the severity of airflow obstruction. In patients with an FEV1/FVC ratio <0.7:[1]

- FEV1 ≥80% predicted indicates mild COPD
- FEV1 <80% and ≥50% predicted indicates moderate COPD
- FEV1 <50% and ≥30% predicted indicates severe COPD
- FEV1 <30% predicted indicates very severe COPD.
Chest x-ray (CXR) is rarely diagnostic but should be performed to exclude other diagnoses. Pulse oximetry screens for hypoxia.

In addition to airflow limitation, the GOLD guidelines recognise the importance of exacerbations in affecting the natural course of COPD, and place emphasis on assessment of symptoms, risk factors for exacerbations, and comorbidities.[1]

The Modified British Medical Research Council (mMRC) questionnaire or the COPD Assessment Test (CAT) are recommended to assess symptoms. These can be found in the GOLD guidelines.[1] GOLD cautions against the use of the mMRC dyspnoea scale alone for assessing patients, as symptoms of COPD go beyond dyspnoea alone. For this reason, the CAT is preferred. However, GOLD acknowledges that the use of the mMRC scale is widespread, and so a threshold of an mMRC grade ≥2 is still included to define ‘more breathless’ patients, as opposed to ‘less breathless’ patients, in its assessment criteria.[1]

The best predictor of frequent exacerbations (two or more per year) is a history of previously treated exacerbations.[48] In addition, the risk of exacerbations is significantly higher in patients with airflow limitation <50% (severe or very severe COPD).[1]

The GOLD guideline uses a combined COPD assessment approach to group patients according to symptoms and previous history of exacerbations. Symptoms are assessed using the mMRC or CAT scale.

- **Group A**: low risk (0-1 exacerbation per year, not requiring hospitalisation) and fewer symptoms (mMRC 0-1 or CAT <10)
- **Group B**: low risk (0-1 exacerbation per year, not requiring hospitalisation) and more symptoms (mMRC ≥ 2 or CAT ≥ 10)
- **Group C**: high risk (≥2 exacerbations per year, or one or more requiring hospitalisation) and fewer symptoms (mMRC 0-1 or CAT <10)
- **Group D**: high risk (≥2 exacerbations per year, or one or more requiring hospitalisation) and more symptoms (mMRC ≥ 2 or CAT ≥ 10).

UK guidelines recommend a full blood count (FBC) for all newly diagnosed patients to screen for anaemia or polycythaemia.[2]

**Other tests**

Detailed pulmonary function tests performed in specialist pulmonary function laboratories can measure flow volume loops and inspiratory capacity. They are not used routinely but can be helpful in resolving diagnostic uncertainties and for preoperative assessment. Diffusing capacity of the lung for carbon monoxide (DLCO) was previously only measured in specialist laboratories; however, portable systems are now available, allowing measurements to be taken in the field. International guidelines from GOLD recommend a DLCO measurement if a patient with COPD has dyspnoea that is disproportionate to their degree of airflow obstruction. A low DLCO value (<60% predicted) in a patient with COPD is associated with decreased exercise capacity, worse health status, and increased risk of death.[1] Serial peak flow measurements may distinguish COPD from asthma if there is diagnostic uncertainty.[2]

In young patients (<45 years) with a family history or with rapidly progressing disease and lower lobe changes on imaging tests, alpha-1 antitrypsin level should be checked. The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once, especially in areas with high prevalence of alpha-1 antitrypsin deficiency.[49] This may aid in family screening and counselling.
Computed tomography scans show anatomical changes, but their usefulness in diagnosis is confined to patients considered for surgery and for ruling out other pathologies, such as bronchiectasis or lung cancer.[1] Annual low-dose CT scan (LDCT) is recommended by the US Preventive Services Task Force (USPSTF) for lung cancer screening in patients with COPD that is due to smoking.[50]

Pulse oximetry should be used to assess all patients with clinical signs of respiratory failure or right heart failure. If peripheral arterial oxygen saturation is less than 92%, then arterial or capillary blood gases should be measured.[1]

Obstructive sleep apnoea is associated with increased risk of death and hospitalisation in patients with COPD.[51]

Exercise testing can be useful in patients with a disproportional degree of dyspnoea.[52] It can be performed on a cycle or treadmill ergometer, or by a simple timed walking test (e.g., 6 minutes, or duration <6 minutes).[53] Exercise testing is also of use in selecting patients for rehabilitation. Respiratory muscle function may also be tested if dyspnoea or hypercapnia are disproportionately increased with respect to FEV1, as well as in patients with poor nutrition and those with corticosteroid myopathy.[54]

In patients with frequent exacerbations, severe airflow limitation, and/or exacerbations requiring mechanical ventilation, sputum should be sent for culture.[1] Echocardiogram evaluates suspected cardiac disease or pulmonary hypertension.[2]


### History and exam

#### Key diagnostic factors

**cough (common)**

- Usually the initial symptom of COPD.
- Frequently a morning cough, but becomes constant as disease progresses.
- Usually productive, and sputum quality may change with exacerbations or superimposed infection.

**shortness of breath (common)**

- Initially with exercise but may progress to shortness of breath even at rest.
- Patients may have difficulty speaking in full sentences.

**sputum production (common)**

- Any pattern of chronic sputum production may indicate COPD.

**exposure to risk factors (common)**

- Including exposure to tobacco smoke, air pollution, or indoor solid fuel burning; occupational exposure to dusts, chemicals, vapors, fumes, or gases; genetic factors and developmentally abnormal lung.
Other diagnostic factors

barrel chest (common)

- The anteroposterior diameter of the chest is increased.
- This suggests hyperinflation and air trapping secondary to incomplete expiration.

hyper-resonance on percussion (common)

- Caused by hyperinflation and air trapping secondary to incomplete expiration.

distant breath sounds on auscultation (common)

- Caused by barrel chest, hyperinflation, and air trapping.

poor air movement on auscultation (common)

- Secondary to loss of lung elasticity and lung tissue breakdown.

wheezing on auscultation (common)

- A common finding in exacerbations. The current accepted descriptive word for a continuous musical lung sound.
- Is indicative of airway inflammation and resistance.

coarse crackles (common)

- A common finding in exacerbations. A discontinuous sound referring to mucus or sputum in airways.
- Indicative of airway inflammation and mucus over-secretion.

Tachypnoea (uncommon)

- An increased respiratory rate occurs to compensate for hypoxia and hypoventilation.
- May involve use of accessory muscles.

asterixis (uncommon)

- Loss of postural control in outstretched arms (commonly known as a flap) caused by hypercapnia.
- This is due to impaired gas exchange in lung parenchyma, worsens with exercise, and is suggestive of respiratory failure.

distended neck veins (uncommon)

- Occurs secondary to increased intrathoracic pressure and cor pulmonale.

lower-extremity swelling (uncommon)

- Suggests cor pulmonale and secondary pulmonary hypertension as a complication of advanced chronic lung disease.

fatigue (uncommon)

- Occurs because of disrupted sleep secondary to constant nocturnal cough and persistent hypoxia and hypercapnia.

weight loss (uncommon)

- May occur secondary to anorexia.
Chronic obstructive pulmonary disease (COPD)

**Diagnosis**

- **muscle loss (uncommon)**
  - Common in patients with severe or very severe COPD.

- **headache (uncommon)**
  - May occur due to vasodilation caused by hypercapnia.

- **pursed lip breathing (uncommon)**
  - Involuntary technique to prolong expiration and decrease air trapping.

- **cyanosis (uncommon)**
  - Seen in the late stages of COPD, usually with hypoxia, hypercapnia, and cor pulmonale.

- **loud P2 (uncommon)**
  - Sign of advanced COPD.
  - Indicates secondary pulmonary hypertension as a complication of cor pulmonale.

- **hepatojugular reflux (uncommon)**
  - Sign of advanced COPD complicated by cor pulmonale.

- **hepatosplenomegaly (uncommon)**
  - Sign of advanced COPD complicated by cor pulmonale.

- **clubbing (uncommon)**
  - COPD itself does not cause clubbing. The presence of clubbing should alert the clinician to a related condition (e.g., lung cancer or bronchiectasis).

**Risk factors**

**Strong**

- **cigarette smoking**
  - Most important risk factor.[12] It causes 40% to 70% of cases of COPD.[17] Passive exposure to cigarette smoke also increases risk of COPD.
  - Elicits an inflammatory response and causes cilia dysfunction and oxidative injury.

- **advanced age**
  - The effect of age may be related to a longer period of cigarette smoking as well as the normal age-related loss of FEV1.

**Genetic factors**

- Airway responsiveness to inhaled insults depends on genetic factors. Alpha-1 antitrypsin deficiency is a genetic disorder, mostly encountered in people of northern European ancestry, which causes panacinar emphysema in lower lobes at a young age. One European study estimated that approximately 1 in every 850 patients with COPD has an alpha-1 antitrypsin protease inhibitor ZZ genotype, which is associated with severe disease.[32] A systematic review and meta-analysis has shown that the prevalence of COPD in adult offspring of people with COPD is greater than population-based estimates.[33]
lung growth and development

- The risk of developing COPD can be increased by processes that affect optimal lung growth and therefore lung function.[26] These processes may go back as far as gestation, birth, childhood, and adolescence. For example, there is a positive association between birthweight and FEV1 in adulthood. Disadvantageous factors in childhood may be as important as heavy smoking in predicting lung function in adulthood.[27] Frequent childhood infection may cause scarring of lungs, decrease elasticity, and increase risk for COPD. History of tuberculosis is associated with increased risk COPD.[34]

Weak white ancestry

- COPD is more common in white people than black and South Asian people, after adjusting for smoking, age, sex, and socioeconomic status.[35]

exposure to air pollution

- Chronic exposure to dust, traffic exhaust fumes, sulfur dioxide, nitrogen dioxide, and particulate matter increases risk of COPD.[12] [18] [19]

exposure to burning solid or biomass fuel

- Household exposure to burning coal or biomass fuel increases the risk of COPD.[36]

occupational exposure to dusts, chemicals, pesticides, vapors, fumes, or gases

- Approximately 14% of all cases of COPD are attributable to occupational exposure.[37] [20]

male sex

- COPD is more common in men, likely due to more smokers being male. However, there is a suggestion that women may be more susceptible than men to the effects of tobacco smoke.[38] [39] [40] [41]

low socio-economic status

- The risk for developing COPD is increased in people with lower socio-economic status.[42] However, this may reflect exposure to cigarette smoke, pollutants, or other factors.

rheumatoid arthritis

- Epidemiological studies indicate an association between risk of COPD and history of rheumatoid arthritis.[34] A meta-analysis showed that compared with controls, patients with rheumatoid arthritis have a significantly increased risk of incident COPD with a pooled relative risk of 1.82.[43]
## Investigations

### 1st test to order

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>spirometry</strong></td>
<td>FEV1/FVC ratio &lt;0.70; total absence of reversibility is neither required nor the most typical result</td>
</tr>
<tr>
<td>• Test establishes FEV1 and FVC. The ratio of these two values indicates whether airflow obstruction is present. COPD severity is classified based on the patient's FEV1 and its percentage of the predicted FEV1. In cases where FVC may be hard to measure, FEV6 (forced expiratory volume at 6 seconds) can be used.^[47]</td>
<td></td>
</tr>
<tr>
<td>• Spirometry should be performed after administering an adequate dose of at least one short-acting inhaled bronchodilator to minimise variability.[1]</td>
<td></td>
</tr>
<tr>
<td><strong>standardised symptoms score</strong></td>
<td>mMRC score ranges from 0-4; CAT score ranges from 0-40: mMRC ≥2 or CAT score ≥10 indicates higher symptoms burden</td>
</tr>
<tr>
<td>• In addition to airflow limitation, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recognise the importance of exacerbations in affecting the natural course of COPD, and place emphasis on assessment of symptoms, risk factors for exacerbations, and comorbidities.[1]</td>
<td></td>
</tr>
<tr>
<td>• The Modified British Medical Research Council (mMRC) questionnaire or the COPD Assessment Test (CAT) are recommended to assess symptoms. These can be found in the GOLD guidelines.[1] GOLD cautions against the use of the mMRC dyspnoea scale alone for assessing patients, as symptoms of COPD go beyond dyspnoea alone. For this reason, the CAT is preferred. However, GOLD acknowledges that the use of the mMRC scale is widespread, and so a threshold of an mMRC grade ≥2 is still included to define 'more breathless' patients, as opposed to 'less breathless' patients, in its assessment criteria.[1]</td>
<td></td>
</tr>
<tr>
<td><strong>pulse oximetry</strong></td>
<td>low oxygen saturation</td>
</tr>
<tr>
<td>• Checked as part of vital signs on acute presentation. A good pulse wave should be picked up by the device. In patients with chronic disease, an oxygen saturation of 88% to 90% may be acceptable.</td>
<td></td>
</tr>
<tr>
<td>• If &lt;92% arterial or capillary blood gases should be checked.[1]</td>
<td></td>
</tr>
<tr>
<td><strong>ABG</strong></td>
<td>PaCO₂ &gt;50 mmHg and/or PaO₂ of &lt;60 mmHg suggests respiratory insufficiency</td>
</tr>
<tr>
<td>• Checked in patients who are acutely unwell, especially if they have an abnormal pulse oximetry reading. Should also be performed in stable patients with FEV1 &lt;35% predicted or with clinical signs suggestive of respiratory failure, or if peripheral arterial oxygen saturation is &lt;92%.</td>
<td></td>
</tr>
<tr>
<td>• Hypercapnia, hypoxia, and respiratory acidosis are signs of impending respiratory failure and possible need for intubation.</td>
<td></td>
</tr>
<tr>
<td><strong>CXR</strong></td>
<td>hyperinflation</td>
</tr>
<tr>
<td>• Seldom diagnostic, but useful in ruling out other pathologies.</td>
<td></td>
</tr>
<tr>
<td>• Increased anteroposterior ratio, flattened diaphragm, increased intercostal spaces, and hyperlucent lungs may be seen.</td>
<td></td>
</tr>
<tr>
<td>Test</td>
<td>Result</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>COPD chest x-ray (AP view):</strong></td>
<td>hyperinflated lung, flattened diaphragm, increased intercostal spaces</td>
</tr>
<tr>
<td>From the collection of Manoochehr Abadian Sharifabad, MD</td>
<td></td>
</tr>
</tbody>
</table>
## Diagnosis

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
</table>
| **COPD chest x-ray (lateral view):** *hyperinflated lung, flattened diaphragm, increased antero-posterior diameter (barrel chest) in lateral view*  
   *From the collection of Manoochehr Abadian Shariatbad, MD*  
   - May also demonstrate complications of COPD, such as pneumonia and pneumothorax. | |
| **FBC**  
   - This test may be considered to assess severity of an exacerbation and may show polycythaemia (haematocrit >55%), anaemia, and leucocytosis. UK guidelines advise FBC in all newly diagnosed patients.[2] | **raised haematocrit, anaemia, possible increased WBC count** |
| **ECG**  
   - Risk factors for COPD are similar to those for ischaemic heart disease, so comorbidity is common. Right-sided heart failure may develop in longstanding COPD (cor pulmonale). | **signs of right ventricular hypertrophy, arrhythmia, ischaemia** |
### Other tests to consider

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>pulmonary function tests</strong></td>
<td>obtrusive pattern, decreased DLCO (&lt;60% predicted)</td>
</tr>
<tr>
<td>- Detailed pulmonary function tests performed in specialist pulmonary function laboratories can measure flow volume loops and inspiratory capacity. They are not used routinely but can be helpful in resolving diagnostic uncertainties and for preoperative assessment.</td>
<td></td>
</tr>
<tr>
<td>- Diffusing capacity of the lung for carbon monoxide (DLCO) was previously only measured in specialist laboratories; however, portable systems are now available, allowing measurements to be taken in the field. International guidelines from GOLD recommend a DLCO measurement if a patient with COPD has dyspnoea that is disproportionate to their degree of airflow obstruction. A low DLCO value (&lt;60% predicted) in a patient with COPD is associated with decreased exercise capacity, worse health status, and increased risk of death. [1]</td>
<td></td>
</tr>
<tr>
<td><strong>chest CT scan</strong></td>
<td>hyperinflation</td>
</tr>
<tr>
<td>- Provides better visualisation of type and distribution of lung tissue damage and bulla formation than CXR.</td>
<td></td>
</tr>
</tbody>
</table>

**COPD chest CT: hyperinflated lung, emphysematous changes, and increased antero-posterior diameter (barrel chest)**

*From the collection of Manoochehr Abadian Sharitab, MD*

- In contrast to smoking-related COPD, alpha-1 antitrypsin deficiency mainly affects lower fields.
- Useful in excluding other underlying pulmonary disease, such as bronchiectasis or lung cancer, and for preoperative assessment. Annual low-dose CT scan (LDCT) is recommended by the US Preventive Services Task Force for lung cancer screening in patients with COPD that is due to smoking.[50]

<table>
<thead>
<tr>
<th>serial peak flow measurement</th>
<th>&lt;20% diurnal or day-to-day variability</th>
</tr>
</thead>
<tbody>
<tr>
<td>- May be used to exclude asthma if there is diagnostic uncertainty. [2]</td>
<td></td>
</tr>
<tr>
<td>Test</td>
<td>Result</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>sputum culture</td>
<td>In patients with frequent exacerbations, severe airflow limitation, and/or exacerbations requiring mechanical ventilation, sputum should be sent for culture.[1]</td>
</tr>
<tr>
<td>alpha-1 antitrypsin level</td>
<td>Low level in patients with alpha-1 antitrypsin deficiency. Test is done if there is high suspicion for alpha-1 antitrypsin deficiency, such as a positive family history and atypical COPD cases (young patients and non-smokers). The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once, especially in areas with high prevalence of alpha-1 antitrypsin deficiency.[49]</td>
</tr>
<tr>
<td>exercise testing</td>
<td>Can be of value in patients with a disproportional degree of dyspnoea compared with spirometry.[52] It can be performed on a cycle or treadmill ergometer, or by a simple timed walking test (e.g., 6 minutes, or duration &lt;6 minutes).[53] Exercise testing is of use in selecting patients for rehabilitation.</td>
</tr>
<tr>
<td>sleep study</td>
<td>Obstructive sleep apnoea, a common finding in patients with COPD, is associated with increased risk of death and hospitalisation in patients with COPD.[51]</td>
</tr>
<tr>
<td>respiratory muscle function</td>
<td>Respiratory muscle function may be tested if dyspnoea or hypercapnia are disproportionately increased with respect to FEV1, as well as in patients with poor nutrition and those with corticosteroid myopathy.[54]</td>
</tr>
<tr>
<td>echocardiogram</td>
<td>To assess cardiac status if cardiac disease or pulmonary hypertension are suspected.[2]</td>
</tr>
</tbody>
</table>
### Differentials

<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>• Onset of asthma is usually in early life. A personal or family history of allergy, rhinitis, and eczema is often present. There is daily variability in symptoms, and patients have overt wheezing that usually rapidly responds to bronchodilators. Cough variant asthma mimics many features of COPD.</td>
<td>• Spirometry shows reversibility with bronchodilators. Pulmonary function tests show reversibility with bronchodilators and no decrease in diffusing capacity of the lung for carbon monoxide (DLCO). Sputum or blood eosinophilia is suggestive of asthma, although may also be present in COPD.</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>• Usually a history of cardiovascular diseases is present. Patients report symptoms of orthopnoea, and fine bibasilar inspiratory crackles may be heard on auscultation.</td>
<td>• B-type natriuretic peptide levels are usually elevated, and chest x-ray reveals increased pulmonary vascular congestion. Echocardiogram may confirm the diagnosis.</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>• There may be a history of recurrent infection in childhood. Large volume of purulent sputum is usually present. Coarse crackles may be heard on auscultation. History of pertussis or tuberculosis is a clue to diagnosis.</td>
<td>• Chest CT reveals bronchial dilation and bronchial wall thickening.</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>• A history of fever, night sweats, weight loss, and chronic productive cough is usually present. Tuberculosis is more common in immigrants to non-endemic countries, and in people living in endemic countries.</td>
<td>• The diagnosis requires microbiological confirmation. Infiltrates, fibrosis, or granuloma seen on chest x-ray or chest CT may suggest tuberculosis. Patients usually have positive skin test for tuberculosis.</td>
</tr>
<tr>
<td>Bronchiolitis</td>
<td>• Bronchiolitis may affect patients at younger ages. The patient may have a history of connective tissue disorders, especially rheumatoid arthritis, or fume exposure. Some cases are post-infectious.</td>
<td>• Pulmonary function tests in bronchiolitis can present with obstructive, restrictive, or mixed pattern. Chest x-ray shows hyperinflation. High-resolution chest CT may show diffuse, small, centrilobular nodular opacities, but is rarely done</td>
</tr>
</tbody>
</table>
**Chronic obstructive pulmonary disease (COPD)**

### Diagnosis

<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests in children due to radiation risk.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Upper airway dysfunction</strong></td>
<td>• Can affect patients of any age. History of prior trauma or intubation is very helpful. Lung examination is usually normal, but signs of upper airway restriction, such as wheezing and stridor, may be present. Patients may have voice hoarseness if vocal cords are involved.</td>
<td>• The flow-volume curve in pulmonary function testing may reveal a characteristic expiratory or inspiratory plateau, or both. Diagnosis is confirmed by direct visualisation of the affected airway by endoscopy.</td>
</tr>
<tr>
<td><strong>Chronic sinusitis/postnasal drip</strong></td>
<td>• Chronic sinusitis/rhinitis is a very common cause of chronic cough. Patients may complain of sinus pressure, rhinorrhoea, non-productive cough, and/or headache.</td>
<td>• Nasal endoscopy, CT of sinuses and/or empirical trial of antihistamines is commonly utilised to aid in diagnosis.</td>
</tr>
<tr>
<td><strong>Gastro-oesophageal reflux disease (GORD)</strong></td>
<td>• Patients with GORD often have dyspepsia and frequent belching, and can have a chronic cough that worsens at night when supine.</td>
<td>• Diagnosis is usually based on response to empirical therapy with proton-pump inhibitors.</td>
</tr>
<tr>
<td><strong>ACE inhibitor-induced chronic cough</strong></td>
<td>• ACE inhibitors can cause chronic cough; however, the cough is usually non-productive.</td>
<td>• Diagnosis is usually based on improvement of symptoms after empirical cessation of ACE inhibitor.</td>
</tr>
<tr>
<td><strong>Lung cancer</strong></td>
<td>• Patients may have weight loss, night sweats, haemoptysis, and/or chest or back pain. • People with COPD are also at increased risk of lung cancer.</td>
<td>• Radiography is important in the assessment for lung cancer. Bronchoscopy may be necessary to evaluate for endobronchial cancer if suspicion is high.</td>
</tr>
</tbody>
</table>

### Criteria

**Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria[1]**

Classification of severity of airflow limitation in COPD:

In pulmonary function testing, a post-bronchodilator FEV1/FVC ratio of <0.70 is commonly considered diagnostic for COPD. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) system categorises airflow limitation into stages. In patients with FEV1/FVC <0.70:

- **GOLD 1 - mild:** FEV1 ≥80% predicted
• GOLD 2 - moderate: $50\% \leq \text{FEV1} < 80\%$ predicted
• GOLD 3 - severe: $30\% \leq \text{FEV1} < 50\%$ predicted
• GOLD 4 - very severe: $\text{FEV1} < 30\%$ predicted.

The GOLD guideline uses a combined COPD assessment approach to group patients according to symptoms and previous history of exacerbations. Symptoms are assessed using the Modified British Medical Research Council (mMRC) or COPD assessment test (CAT) scale. These can be found in the GOLD guidelines.[1] GOLD cautions against the use of the mMRC dyspnoea scale alone for assessing patients, as symptoms of COPD go beyond dyspnoea alone. For this reason, the CAT is preferred. However, GOLD acknowledges that the use of the mMRC scale is widespread, and so a threshold of an mMRC grade ≥2 is still included to define 'more breathless' patients, as opposed to 'less breathless' patients, in its assessment criteria.[1]

• Group A: low risk (0-1 exacerbation per year, not requiring hospitalisation) and fewer symptoms (mMRC 0-1 or CAT <10)
• Group B: low risk (0-1 exacerbation per year, not requiring hospitalisation) and more symptoms (mMRC ≥ 2 or CAT ≥ 10)
• Group C: high risk (≥2 exacerbations per year, or one or more requiring hospitalisation) and fewer symptoms (mMRC 0-1 or CAT <10)
• Group D: high risk (≥2 exacerbations per year, or one or more requiring hospitalisation) and more symptoms (mMRC ≥ 2 or CAT ≥ 10).

Screening

There are no data to show conclusively that screening spirometry is effective in directing management decisions or in improving COPD outcomes in asymptomatic patients.[55] However, if COPD is diagnosed at an early stage and risk factors are eliminated, the rate of decline in lung function will dramatically decrease.[56]

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines advocate early case-finding by performing spirometry in patients with symptoms and/or risk factors for COPD.[1] UK guidelines advise spirometry in all patients aged 35 years or older who are current or former smokers and have a chronic cough, to detect cases at an early stage. Clinicians should also consider conducting screening spirometry in all patients with findings compatible with emphysema on chest x-ray or computed tomography of the chest.[2]

Significant pulmonary dysfunction may be present in asymptomatic smokers.
Approach

For updates on diagnosis and management of coexisting conditions during the coronavirus disease 2019 (COVID-19) pandemic, see our topic 'Management of coexisting conditions in the context of COVID-19'. For details on the management of alpha-1 antitrypsin deficiency, please see our topic 'Alpha-1 antitrypsin deficiency'.

The ultimate goals of treatment of COPD are to prevent and control symptoms, to reduce the severity and number of exacerbations, to improve respiratory capacity for increased exercise tolerance, and to reduce mortality.[1] One systematic review looking at 9 studies found that, compared with placebo, pharmacological treatment for COPD can reduce the rate of decline in FEV1. Overall, the systematic review showed a reduction in the rate of decline in FEV1 of 5.0 mL/year for active treatment arms compared with placebo. For studies with inhaled corticosteroid-containing treatment arms, the difference in decline was 7.3 mL/year compared with placebo, whereas the difference between treatment arms containing long-acting bronchodilator and placebo was 4.9 mL/year.[57] However, further research is needed to find out which patients are most likely to benefit.

There is a stepwise approach to therapy and treatment should be individualised for general health status and comorbid conditions.

The therapeutic approach involves reducing risk factor exposure, appropriate assessment of disease, patient education, pharmacological and non-pharmacological management of stable COPD, and prevention and treatment of acute COPD exacerbations.


Continuous assessment and monitoring of disease

Ongoing monitoring and assessment in COPD ensures that the goals of treatment are being met. Quality of life and patients’ sense of well-being will improve, and hospital admissions will be significantly decreased, when self- or professional monitoring of disease is being utilised.[58] Such assessment of the medical history should include:

Exposure to risk factors and preventative measures:

- Tobacco smoke
- Indoor and outdoor air pollution
- Occupational exposures (fumes, dust, etc.)
- Influenza and pneumococcal vaccination.

Disease progression and development of complications:

- Decline in exercise tolerance
- Increased symptoms
- Worsened sleep quality
- Missed work or other activities.

Pharmacotherapy and other medical treatment:
Chronic obstructive pulmonary disease (COPD) Management

**MANAGEMENT**

- How often rescue inhaler is used
- Any new medicines
- Compliance with medical regimen
- Ability to use inhalers properly
- Adverse effects.

**Exacerbation history**

- Urgent care or emergency department visits
- Recent oral corticosteroid bursts
- Frequency, severity, and likely causes of exacerbations should be evaluated.

**Comorbidities**:

- Assessment of co-existing medical problems (e.g., heart failure) which may add to symptoms and impact prognosis.

In addition, objective assessment of lung function should be obtained yearly, or more frequently if there is a substantial increase in symptoms.

One Cochrane review found that integrated disease management (IDM), in which several healthcare providers (physiotherapist, respiratory physician, nurse, etc.) work together with patients, probably results in improvement in disease-specific quality of life, exercise capacity, hospital admissions, and hospital days per person.[59]

**Acute exacerbations**

An exacerbation of COPD is defined as an event characterised by a change in the patient's baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations and is acute in onset. See our topic on Acute exacerbation of chronic obstructive pulmonary disease for further information.

**Chronic management: stepwise therapy according to GOLD group**

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend that initial treatment is determined by the patient’s GOLD group at diagnosis:[1]

- Rescue short-acting bronchodilators should be prescribed to all patients for immediate symptom relief. Failure to respond to short-acting bronchodilator may signify an acute exacerbation.

- For group A patients (few symptoms and low risk of exacerbations), a short-acting or a long-acting bronchodilator is offered first-line. Long-acting beta-2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are preferred over short-acting bronchodilators, except for patients with only occasional dyspnoea.[1] LABAs and LAMAs both significantly improve lung function, dyspnoea, and health status and reduce exacerbation rates. [Evidence A] LAMAs have a greater effect on exacerbation reduction than LABAs.[60] [61]

- For group B patients (more symptoms and low risk of exacerbations), a long-acting bronchodilator should be offered first-line. Either a LAMA or a LABA may be prescribed. There is no evidence to recommend one class of long-acting bronchodilator over another for initial treatment in this group of patients. The choice should depend on the patient's perception of symptom relief. For patients with severe breathlessness, initial treatment with two bronchodilators of different classes may be warranted. Patients in group B may have comorbidities that add to their symptoms and impact their prognosis, and so any potential comorbidities should be considered and investigated.
**Initial pharmacological treatment**

<table>
<thead>
<tr>
<th>Group C (≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization)</th>
<th>Group A (0 or 1 moderate exacerbations (not leading to hospital admission))</th>
<th>Group D (LAMA or LAMA + LABA* or ICS + LABA**)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LAMA</strong></td>
<td><strong>A bronchodilator</strong></td>
<td><strong>A long acting bronchodilator (LABA or LAMA)</strong></td>
</tr>
</tbody>
</table>

mMRC 0-1, CAT < 10

mMRC ≥ 2, CAT ≥ 10

*Consider if highly symptomatic (e.g. CAT > 20)

**Consider if blood eosinophil count in cells per microliter ≥ 300

Initial pharmacological management of COPD

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report); used with permission

Further treatment is determined by the patient’s dyspnoea/exercise limitation symptom burden and frequency of exacerbations after review and is independent of the patient’s GOLD group at diagnosis. GOLD recommends different treatment pathways depending on whether the primary treatment goal is relieving dyspnoea/exercise limitation symptoms or reducing exacerbations. If treatment is required for both purposes, clinicians should follow the exacerbation pathway. [1]
Before any adjustment in treatment, patients should be reviewed for symptoms and exacerbation risk, and their inhaler technique and treatment adherence should be assessed. The role of non-pharmacological treatment should also be assessed. If the patient’s response to initial treatment is appropriate, then the initial treatment can be maintained. Adjustment of pharmacological treatment can consist of escalation or de-escalation of therapy, as well as switching inhaler devices or molecules within the same drug class. If treatment is changed, then clinicians should review the patient for a clinical response, and for any potential side effects.

Recommended escalation therapy for patients with persistent dyspnoea/exercise limitation after initial therapy is as follows:

- Patients taking long-acting bronchodilator monotherapy should start a second long-acting bronchodilator from a different class. If symptoms do not improve, the second long-acting bronchodilator should be stopped. Changing inhaler device or molecules may be considered.
- For patients taking LABA/ICS therapy, LAMA may be added (triple therapy). Alternatively, LABA/ICS may be switched to LABA/LAMA if the original indication for LABA/ICS was not appropriate, if the patient has not responded to ICS treatment, or if there are significant ICS adverse effects.
- Dyspnoea due to other causes should be considered, investigated, and treated. Inhaler technique and adherence should also be re-assessed, as these may have led to an inadequate response to treatment.

Recommended escalation therapy for patients with persistent exacerbations after initial therapy is as follows:

- Patients taking long-acting bronchodilator monotherapy should increase therapy to either LABA/LAMA or LABA/ICS. Blood eosinophil counts can identify patients who are more likely to respond to ICS. LABA/ICS may be considered in patients with two or more moderate exacerbations per year, or at least one severe exacerbation needing hospital admission in the previous year, and an eosinophil count ≥100 cells/microlitre, or if the history/clinical findings are suggestive of asthma. Patients who have one exacerbation per year are more likely to respond to LABA/ICS if their peripheral eosinophil count is ≥300 cells/microlitre. Patients who take a LABA or LAMA who have blood eosinophils <100 cells/microlitre or who have contraindications to ICS should commence a LABA/LAMA.
- Patients who take LABA/LAMA and whose blood eosinophils are ≥100 cells/microlitre should escalate to triple therapy with LABA/LAMA/ICS. Multiple studies support triple therapy with LABA/LAMA/ICS as being superior to single- or double-agent therapy with LABA/LAMA or LABA/ICS regarding rate of moderate to severe COPD exacerbations and rate of hospitalisation. American Thoracic Society guidelines recommend the use of triple therapy in patients who have had one or more exacerbations requiring oral corticosteroids, antibiotics, or hospitalisation in the past year and who have symptoms of dyspnoea or reduced exercise tolerance despite LABA/LAMA dual therapy. UK guidelines recommend the use of triple therapy in patients who have an exacerbation requiring hospitalisation, or two moderate exacerbations within a year, despite dual therapy with LABA/LAMA.
- Patients who take a LABA/LAMA and whose blood eosinophils are <100 cells/microlitre should add roflumilast or azithromycin.
- Patients who take LABA/ICS should escalate to triple therapy by adding a LAMA. If ICS is ineffective or causing significant adverse effects, patients may switch to LABA/LAMA.
Chronic obstructive pulmonary disease (COPD)

Management

• Patients who take LABA/LAMA/ICS may add roflumilast or azithromycin. Roflumilast may be considered in patients with forced expiratory volume in 1 second (FEV1) <50% predicted and chronic bronchitis, particularly if they have had at least one hospitalisation for an exacerbation in the last year. The risk of developing antibiotic-resistant organisms should be considered when prescribing azithromycin. ICS can be discontinued if it is ineffective or causing adverse effects. Patients with blood eosinophils ≥300 cells/microlitre are at greatest risk of exacerbations after withdrawing ICS.[77]

All patients are candidates for education, vaccination, and smoking cessation interventions.
Chronic obstructive pulmonary disease (COPD)

Management

Follow-up pharmacological treatment

If response to initial treatment is appropriate, maintain it
If not:
• Consider the predominant treatable trait to target (dyspnea or exacerbations)
  Use exacerbation pathway if both exacerbations and dyspnea need to be targeted
• Place patient in box corresponding to current treatment & follow indications
• Assess response, adjust and review
• These recommendations do not depend on the ABCD assessment at diagnosis

Dyspnea

LABA or LAMA

LABA + LAMA

LABA + LAMA + ICS

• Consider switching inhaler device or molecules
• Investigate (and treat) other causes of dyspnea

Exacerbations

LABA or LAMA

LABA + LAMA

LABA + LAMA + ICS

Consider if eos ≥ 100

LABA + LAMA + ICS

Consider if eos < 100

Roflumilast

FEV₁, < 50% & chronic bronchitis

Azithromycin

In former smokers

*Consider if eos ≥ 300 or eos ≥ 100 AND ≥ 2 moderate exacerbations / 1 hospitalization
**Consider de-escalation of ICS or switch if pneumonia, inappropriate original indication or lack of response to ICS

eos: blood eosinophil count in cells per microliter
LABA: long-acting beta-2 agonist
LAMA: long-acting muscarinic antagonist
ICS: inhaled corticosteroid
FEV₁: forced expiratory volume in 1 second

Escalation therapy for patients with COPD

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report). Reproduced with permission
**Bronchodilators**

Beta-2 agonists are widely used in the treatment of COPD. They increase intracellular cAMP, leading to respiratory smooth muscle relaxation and reduced airway resistance. Muscarinic antagonists (anticholinergics) act as bronchodilators by blocking the cholinergic receptors on the respiratory smooth muscle. This causes muscle relaxation and reduces airflow limitation. Beta agonists and muscarinic antagonists, therefore, provide bronchodilator effects through different pathways. Both are available as short-acting and long-acting preparations.

Short-acting beta-2 agonists (e.g., salbutamol) and short-acting muscarinic antagonists (e.g., ipratropium) improve lung function and breathlessness and quality of life. Ipratropium may have a small benefit over short-acting beta-2 agonists in improving health-related quality of life.[78] These agents can be used as rescue therapy when the patient is using long-acting bronchodilator therapy and may be used as initial treatment for patients in GOLD group A if patients only have occasional dyspnoea.[1] [79] However, regular use of short-acting bronchodilators is not generally recommended.

Tiotropium, a LAMA, has been shown to reduce risk of exacerbation versus placebo or other maintenance treatments.[80] Newer LAMAs, such as aclidinium, glycopyrronium, and umeclidinium, have at least comparable efficacy to tiotropium, in terms of change from baseline in trough FEV1, transitional dyspnoea index focal score, St George’s Respiratory Questionnaire score, and rescue medication use.[81] Revefenacin is a nebulised LAMA approved for the maintenance treatment of moderate to severe COPD. There is a suggestion of increased cardiovascular-related mortality in some studies of patients taking short-acting muscarinic antagonists and in some studies of patients taking LAMAs.[82] [83] One study concluded that aclidinium was not associated with an increase in major adverse cardiovascular events, compared with placebo.[84] A population-based cohort study found that older men with COPD newly started on LAMAs are at increased risk of urinary tract infections.[85]

LABAs and LAMAs both significantly improve lung function, dyspnoea, and health status and reduce exacerbation rates. In cases of stable COPD, if the decision is made to use single-agent therapy, LAMA may be superior to LABA agents.[86] LAMAs have a greater effect on exacerbation reduction than LABAs in patients with moderate to very severe COPD.[60] [61] The long-term safety of LAMA was demonstrated in the UPLIFT trial.[87]

A LABA/LAMA combination may provide a better therapeutic effect without increasing the adverse effects of each class.[86] [88] [89] [90] [91] Combination therapy with a LABA/LAMA reduces exacerbation rate compared with monotherapy. Once-daily LABA/LAMA delivered via a combination inhaler is more associated with a clinically significant improvement in lung function and health-related quality of life in patients with mild/moderate COPD, compared with placebo.[92] Compared to LABA/ICS, a LABA/LAMA combination has fewer exacerbations, a larger improvement of FEV1, a lower risk of pneumonia, and more frequent improvement in quality of life.[93] A systematic review and network meta-analysis found that all LABA/LAMA fixed-dose combinations had a similar efficacy and safety.[94]

Umeclidinium/vilanterol, glycopyrronium/formoterol, tiotropium/olodaterol, and aclidinium/formoterol are LABA/LAMA combinations approved for use in COPD. Umeclidinium/vilanterol decreases the risk of exacerbations in patients with mild/moderate COPD.[92]

As outlined above, GOLD makes recommendations on the initial agent based on the patient's risk group (A, B, C, or D).[1] American Thoracic Society guidelines recommend initiating LABA/LAMA dual therapy in preference to monotherapy in patients with COPD who have dyspnoea or exercise intolerance.[76] UK guidelines recommend initiating dual therapy with a LABA/LAMA or LABA/ICS if a patient has symptoms.
or exacerbations despite non-pharmacological treatment and using a short-acting bronchodilator as needed. The choice of initial drug regimen in the UK guidance is based on whether or not the patient has features of asthma or features suggesting corticosteroid responsiveness.[2]

**Inhaled corticosteroids**

When indicated in patients with COPD, ICS should always be prescribed in combination with long-acting bronchodilators. ICS are believed to be effective because of their anti-inflammatory effects. Long-term ICS use reduces the need to use rescue therapy and reduces exacerbations, and may also decrease mortality.[95] [96] [97]

The effect of treatment regimens containing ICS is higher in patients at higher risk of exacerbations (two or more exacerbations and/or one hospitalisation for an exacerbation in the previous year).[69] [71] [98] Blood eosinophil count may predict the effectiveness of adding ICS to regular long-acting bronchodilator treatment to prevent exacerbations.[99] [64] [65] Little or no effect is seen at blood eosinophil counts of <100 cells/microlitre, while maximal effect is seen at blood eosinophil counts of >300 cells/microlitre.[63]

These thresholds indicate approximate cut-off values which may help clinicians predict the likelihood of a treatment benefit.[1] Former smokers are more corticosteroid-responsive than current smokers at any eosinophil count.[99] Both current and former smokers with COPD can benefit from ICS in terms of lung function and rates of exacerbations, although the effect is smaller for heavy or current smokers compared with light or former smokers.[71] [100] Short-term ICS use (≤1 year) may be associated with greater improvements in FEV1 than long-term use, although further studies are needed to better understand the effect of treatment on lung function.[101]

Several studies have pointed to an increased risk of pneumonia in patients with COPD taking ICS.[102] This risk is higher for fluticasone in comparison with budesonide.[103] [104] [105] A study in a large cohort of Danish patients found the risk of acquiring *Pseudomonas aeruginosa*, a common cause of hospital-acquired pneumonia, to be dose-dependent, with high-dose ICS associated with the greatest risk. The study also found that patients with *P aeruginosa* were more likely to have a lower BMI and FEV1 than *P aeruginosa*-negative patients.[106] A systematic review and meta-analysis found that, despite a significant increase in unadjusted risk of pneumonia associated with use of ICS, pneumonia fatality and overall mortality were not increased in randomised controlled trials and were decreased in observational studies.[107] Therefore, an individualised treatment approach that assesses a patient's risk of pneumonia versus the benefit of decreased exacerbations should be implemented.[102] [108] [109] Concern is also raised with regards to increased risk of tuberculosis and influenza in adult patients with COPD who are on ICS therapy, although one meta-analysis found that less than 1% of all assessed tuberculosis cases were attributable to ICS exposure.[110] [111] ICS may also cause oropharyngeal candidiasis and hoarseness.[102]

Although there have been reports of ICS use either increasing or decreasing the risk of lung cancer, the available data do not appear to support either conclusion; further studies are needed.[1]

Clinicians should weigh the potential benefits and risks of prescribing ICS and discuss these with the patient.[2] A history of hospitalisation(s) for exacerbations of COPD, two or more moderate exacerbations per year despite regular long-acting bronchodilators, blood eosinophils of ≥300 cells/microlitre, and/or previous or concomitant asthma all strongly favour initiating ICS.[112] Repeated episodes of pneumonia, blood eosinophils <100 cells/microlitre, and/or history of mycobacterial infection are all factors against the use of ICS.[112] Use of ICS can be considered in patients with one moderate exacerbation of COPD
per year despite regular long-acting bronchodilator therapy and/or peripheral eosinophils 100-300 cells/microlitre.[112]

The European Respiratory Society has produced a guideline on the withdrawal of inhaled corticosteroids in COPD.[113]

Long-term use of oral corticosteroids in COPD is not recommended.[76] Some patients with severe disease are unable to completely stop treatment after starting oral corticosteroids for an acute exacerbation. In this case, the dose should be kept as low as possible and consideration given to osteoporosis prophylaxis.[2]

**Combined bronchodilator and corticosteroid preparations**

A combination preparation of a long-acting bronchodilator and an ICS may be used for patients who require both these agents. This is convenient and may help with compliance in some patients. The choice of therapy in this class is based on availability and individual response and preference.[114] Combination therapy with an ICS and a LABA is superior to use of either agent alone.[115] [116] The combination may be provided in separate inhalers or a combination inhaler.

Multiple studies support triple therapy with LABA/LAMA/ICS as being superior to single- or double-agent therapy with LABA/LAMA or LABA/ICS regarding rate of moderate to severe COPD exacerbations and rate of hospitalisation.[67] [68] [69] [70] [71] [72] [73] [74] [75] Use of ICS also slows the rate of decline in lung function following an exacerbation in patients with mild to moderate COPD and elevated blood eosinophils.[117] One randomised controlled trial has reported a reduction in all-cause mortality in patients with FEV1 <50% and at least one exacerbation in the past year who take fluticasone furoate/umeclidinium/vilanterol, compared with patients taking umeclidinium/vilanterol. Patients with mild COPD and at least two moderate or one severe exacerbations in the last year also had reduced all-cause mortality when taking fluticasone furoate/umeclidinium/vilanterol, compared with umeclidinium/vilanterol.[118] Another randomised controlled trial had similar findings in terms of mortality in the triple therapy arm (budesonide/glycopyrronium/formoterol), but only at the higher dose of ICS.[75] [119] The same study showed that increasing the dose of budesonide in triple therapy does not decrease the rate of exacerbations, compared with standard dose triple therapy.[75] For both studies, there were no differences in mortality compared with LABA/ICS.[75] [118] [119] A post hoc pooled analysis of three trials of triple therapy in patients with COPD and severe airflow limitation and a history of exacerbations showed a non-significant trend for lower mortality with triple therapy compared with non-ICS treatments.[120] These results are strengthened by findings from a meta-analysis of over 200 studies: triple therapy provided a significant reduction in mortality versus dual therapy, although was associated with greater risk of pneumonia. No differences were observed between regimens in lung function or health-related quality of life.[121]

Before prescribing triple therapy, clinicians should assess whether another physical or mental condition could be causing the patient’s symptoms. UK guidelines advise clinicians to review patients taking triple therapy for relief of daily symptoms after 3 months. Treatment should be changed to LABA/LAMA if the patient’s symptoms have not improved.[2] The ICS may be withdrawn if the patient has had no exacerbations in the past year.[76] One systematic review of data from real-world studies found little to no evidence of worsened outcomes when ICS was withdrawn and followed by appropriate pharmacological management in patients with moderate to severe COPD.[122]
**Phosphodiesterase-4 inhibitors**

Roflumilast is an oral phosphodiesterase-4 inhibitor which inhibits the breakdown of cAMP. It may be considered in patients with FEV1 <50% predicted and chronic bronchitis who are taking LABA/LAMA/ICS, particularly if they have had at least one hospitalisation for an exacerbation in the last year.[1] Roflumilast offers benefit in improving lung function and reducing the likelihood of exacerbations. However, it has little impact on quality of life or symptoms.[123]

**Antibiotics**

Prophylactic antibiotics, such as macrolides, may be considered for reducing the risk of acute exacerbation, particularly in patients who have frequent exacerbations and are refractory to standard therapy.[124] A Cochrane review ranked macrolides first in reducing exacerbations and serious adverse events, and improving quality of life, above fluoroquinolones and tetracyclines.[127] Use of prophylactic macrolide antibiotics decreases the frequency of exacerbations in patients with COPD but long-term azithromycin use is associated with clinically significant hearing loss, which in many cases was reversible.[128] There are no data showing the efficacy or safety of chronic azithromycin treatment beyond 1 year of treatment.

Azithromycin therapy is believed to be most effective in preventing acute exacerbation, with greater efficacy seen in older patients and milder GOLD stages. Little evidence of treatment benefit is seen in current smokers.[129] Azithromycin increases the risk of colonisation with macrolide-resistant organisms and should not be prescribed for patients with hearing impairment, resting tachycardia, or apparent risk of QTc prolongation.[130] Azithromycin should be considered preferentially, but not only, in former smokers with persistent exacerbations despite appropriate therapy.[1]

UK guidelines advise that prophylactic azithromycin could be considered for patients who have more than three acute exacerbations requiring corticosteroid therapy and at least one exacerbation requiring hospitalisation per year.[131] Before starting prophylactic antibiotics, baseline ECG and liver function tests should be performed, a sputum sample obtained for culture and sensitivity (including tuberculosis testing), the patient’s sputum clearance technique should be optimised, and bronchiectasis should be excluding with a CT scan.[2] ECG and liver tests should be repeated after 1 month of treatment. A head-to-head comparison of fluoroquinolones, tetracyclines, and macrolides given for 12 to 13 weeks to people with COPD did not identify a difference in efficacy or safety between antibiotic classes, but the sample sizes of included studies were small and the studies were of short duration; further research is required in this area.[132]

Prophylactic antibiotic therapy should be reviewed at 6 and 12 months to determine whether there is a benefit in terms of exacerbation rates.[131] If antibiotic therapy is not effective it should be stopped.

**Methylxanthines**

Theophylline (a methylxanthine agent) is a bronchodilator that acts by increasing cAMP and subsequent respiratory smooth muscle relaxation. It is not commonly used because of limited potency, narrow therapeutic window, high risk profile, and frequent drug-drug interactions. Theophylline is indicated for persistent symptoms if inhaled therapy is insufficient to relieve airflow obstruction. Theophylline has modest effects on lung function in moderate to severe COPD.[133] A large randomised controlled trial found no effect of oral theophylline alone or with prednisolone on exacerbations of severe COPD.[134] GOLD advise that theophylline should only be used if other long-term bronchodilator treatments are
unavailable or unaffordable.[1] Experts may prescribe theophylline after a patient has exhausted all options for inhaled therapies.

**Patient education and self-management**

All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. It is important to remember that no medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications.

One Cochrane review found that self-management interventions that include an action plan for acute exacerbations of COPD are associated with improvements in health-related quality of life and fewer admissions to hospital for respiratory problems. An exploratory analysis found a small, but significantly higher, respiratory-related mortality rate for self-management compared to usual care, although no excess risk of all-cause mortality was seen.[135] A randomised controlled trial showed that a 3-month programme of self-management started in patients with COPD exacerbations recently discharged from hospital led to increases in COPD-related hospitalisations and emergency department visits over 6 months.[136]

Self-management plans should include personalised advice on: breathlessness and stress management techniques, energy conservation, avoiding aggravating factors, how to monitor symptoms, how to manage worsening symptoms, and contact information to use in the event of an exacerbation.[1]

Helping patients to self-manage should ideally address psychosocial concerns and patients’ personal beliefs about COPD and its management. Many patients report losses and limitations on their lifestyle and social interaction after a diagnosis of COPD. It is estimated that patients with COPD are 1.9 times more likely to commit suicide than those without COPD, and symptoms of anxiety, depression, and frustration are common.[137] [138] Studies have found a beneficial effect of cognitive behavioural therapy (CBT) on outcomes including symptoms of depression and anxiety, quality of life, and frequency of emergency department visits.[139] [140] [141] Further research is warranted into the effects of high-resource-intensive versus low-resource-intensive CBT.[141]

One randomised controlled trial found that a telephone health coaching intervention to promote behaviour change in patients with mild COPD in primary care led to improvements in self-management activities, but did not improve health-related quality of life.[142] A meta-analysis found that health coaching that included goal setting, motivational interviewing, and COPD-related health education significantly improved health-related quality of life and reduced hospital admissions for an exacerbation of COPD, but did not decrease all-cause hospital admissions.[143]

Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control.[144] [145] Poor technique is more likely when patients are using multiple devices or have never received inhaler technique training.[146] Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.[147] Demonstration using a placebo device may be most effective for teaching inhaler technique to adults aged ≥65 years.[148] Patients should be asked to bring their inhalers to clinic to facilitate a review of inhaler use.[1] Pharmacist-led interventions and lay health coaching can improve inhaler technique and adherence in patients with COPD.[149] [150] Inhaler device attributes such as rapid onset of symptom relief and small size have been recorded in patient preference studies.[151] [152]
Physical activity is recommended for all patients with COPD.\[1\] One systematic review and meta-analysis of randomised controlled trials found that exercise training on its own can improve physical activity in COPD, and greater improvements can be made with the addition of physical activity counselling.\[153\] Another systematic review and meta-analysis found that a combination of aerobic exercise and strength training was more effective than strength training or endurance training alone in increasing the 6-minute walking distance.\[154\] Other studies have demonstrated improvements in peak oxygen uptake, perceived fatigue, and health-related quality of life following adherence to supervised and unsupervised exercise programmes.\[155\] \[156\] \[157\] A Cochrane review found limited evidence for improvement in physical activity with physical activity counselling, exercise training, and pharmacological management of COPD. The authors commented that assessment of quality had been limited by lack of methodological detail and the diverse range of interventions had primarily been assessed in single studies.\[158\] The optimal timing, components, duration, and models for improving physical activity remain unclear. Meta-analyses suggest that yoga, Qigong, and other home-based breathing exercises can improve exercise capacity and pulmonary function in patients with COPD.\[159\] \[160\] \[161\] Tai Chi has been shown to improve exercise capacity compared with usual care.\[162\]

Dietary advice and oral supplements have been found to improve body weight, quality of life, respiratory muscle strength, and 6-minute walk distance.\[163\] \[164\] However, nutritional support has not been consistently found to improve lung function.\[164\]

**Smoking cessation and vaccination**

Smoking cessation should be encouraged in all patients, in addition to guidance on avoiding exposure to occupational or environmental tobacco smoke and other irritants.\[1\] \[2\] Smoking cessation significantly reduces the rate of progression of COPD and risk of malignancies. It also reduces the risk of coronary and cerebrovascular diseases. Among different therapeutic modalities in COPD, the only two factors that improve survival are smoking cessation and oxygen supplementation.

Usual smoking-cessation programmes include counselling, group meetings, and drug therapy.\[165\] Some patients may need frequent referrals to achieve success. Smoking cessation that includes pharmacotherapy and intensive counselling has a higher success rate and is cost effective in COPD, with low costs per quality-adjusted life year.\[166\] \[167\] \[168\] The effectiveness and safety of e-cigarettes/vaping as an aid to smoking cessation is uncertain.\[1\]

Depending on local guidelines, patients should be vaccinated against influenza virus, *Streptococcus pneumoniae*, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19).\[1\] \[169\]

Vaccination against influenza is associated with fewer exacerbations of COPD.\[170\] \[171\] Guidance from the US Centers for Disease Control and Prevention (CDC) advises a single dose of pneumococcal 23-valent polysaccharide vaccine (PPSV23) for all patients with COPD who have not previously received the recommended pneumococcal vaccine. The CDC recommends that all adults aged 65 years and over should receive one dose of PPSV23. The CDC also recommends shared decision-making regarding administration of the PCV13 (pneumococcal 13-valent conjugate vaccine) to people aged 65 years and older who do not have an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant, and who have not previously received PCV13. If a decision to give PCV13 is made, PCV13 should be given first, followed by PPSV23 at least 1 year later.\[172\]
The CDC also recommends the tetanus/diphtheria/pertussis vaccine in people with COPD who were not vaccinated in adolescence, and varicella-zoster virus (shingles) for adults with COPD aged 50 years and over.\[169\]

**Mucolytics**

Patients with the chronic bronchitis phenotype of COPD often produce thick sputum on a frequent basis. Mucolytic agents are not associated with an increase in adverse effects and may be beneficial during exacerbations of COPD. They result in a small reduction in the frequency of acute exacerbations and in days of disability per month, but do not improve lung function or quality of life.\[173\] One meta-analysis comparing erdosteine, carbocisteine, and acetylcysteine concluded that erdosteine had the most favourable safety and efficacy profile. Erdosteine reduced the risk of hospitalisation due to an acute exacerbation, and erdosteine and acetylcysteine reduced the duration of an acute exacerbation.\[174\] Another meta-analysis found that acetylcysteine significantly reduced the frequency of exacerbations compared with placebo, without increasing the risk of adverse effects. The authors concluded that 3 months of treatment with a low dosage was effective.\[175\] Erdosteine and carbocisteine are not available in the US and some other countries. Treatment with mucolytic agents such as carbocisteine and acetylcysteine may reduce exacerbations and modestly improve health status in patients not receiving ICS.\[1\] However, erdosteine may have a significant effect on mild exacerbations whether or not the patient is taking ICS.\[1\]

**Pulmonary rehabilitation**

Pulmonary rehabilitation comprises aerobic exercise, strength training, and education. It should be initiated for patients who remain symptomatic despite bronchodilator therapy and is recommended to start early in the course of the disease, when they start feeling shortness of breath with regular activity and walking on a level surface. GOLD guidelines recommend pulmonary rehabilitation for patient groups B to D.\[1\]

Pulmonary rehabilitation relieves dyspnoea and fatigue, improves emotional function, and enhances a sense of control to a moderately large and clinically significant extent.\[176\] Extensive pulmonary rehabilitation following hospital admission with an acute exacerbation of COPD decreases the risk of readmission, improves health-related quality of life, and reduces mortality. There is evidence to support starting pulmonary rehabilitation within 1 month of an acute exacerbation.\[177\] \[178\]

A large US cohort study found that initiation of pulmonary rehabilitation within 90 days of hospital discharge was significantly associated with lower mortality risk at 1 year and fewer rehospitalisations at 1 year.\[179\] \[180\] Less than 2% of the patient cohort initiated rehabilitation within this timeframe, highlighting the need to develop more effective strategies to encourage patient participation.\[179\] However, starting pulmonary rehabilitation before hospital discharge could be associated with a higher 12-month mortality, so is not recommended.\[181\]

Pulmonary rehabilitation also decreases the depression and anxiety related to COPD, and reduces hospitalisation.\[182\]

The benefit of pulmonary rehabilitation appears to subside after termination of the course unless patients follow a home exercise schedule.\[183\] Maintenance pulmonary rehabilitation, defined as ongoing supervised exercise at a lower frequency than the original rehabilitation programme, may have a role in preserving the benefits of pulmonary rehabilitation over time. Findings from a Cochrane review indicate
that supervised maintenance programmes may improve health-related quality of life and exercise capacity at 6 to 12 months compared with usual care.[184]

Benefits of home- or community-based pulmonary rehabilitation on respiratory symptoms and quality of life in patients with COPD can match those of the hospital-based rehabilitation programmes.[185] [186] [187] A Cochrane review concluded that both primary and maintenance telerehabilitation achieved similar outcomes to in-person rehabilitation with no safety issues. Limitations of the review include small patient numbers and heterogeneity in telerehabilitation models.[188]

**Oxygen therapy and ventilatory support**

GOLD guidelines recommend long-term oxygen therapy in stable patients who have:[1]

- \( \text{PaO}_2 \leq 7.3 \text{ kPa (55 mmHg)} \) or \( \text{SaO}_2 \leq 88\% \), with or without hypercapnia confirmed twice over a 3-week period; or
- \( \text{PaO}_2 \) between 7.3 kPa (55 mmHg) and 8.0 kPa (60 mmHg), or \( \text{SaO}_2 \) of 88%, if there is evidence of pulmonary hypertension, peripheral oedema suggesting congestive cardiac failure, or polycythaemia (haematocrit > 55%).

Guidelines from the American Thoracic Society (ATS) recommend prescribing long-term oxygen therapy for at least 15 hours per day in adults with COPD who have severe chronic resting room air hypoxaemia. The ATS defines severe hypoxaemia as either:[189]

- \( \text{PaO}_2 \leq 7.3 \text{ kPa (55 mmHg)} \) or oxygen saturation as measured by pulse oximetry (\( \text{SpO}_2 \)) \leq 88\%; or
- \( \text{PaO}_2 7.5-7.9 \text{ kPa (56-59 mmHg)} \) or \( \text{PaO}_2 \) of 89% plus one of the following: oedema, haematocrit \geq 55%, or P pulmonale on an ECG.

For patients prescribed home oxygen therapy, the ATS recommends that the patient and their caregivers should receive instruction and training on the use and maintenance of all oxygen equipment and education on oxygen safety, including smoking cessation, fire prevention, and tripping hazards.[189]

Supplemental oxygen should be titrated to achieve \( \text{SaO}_2 \geq 90\% \).[1] The patient should be reassessed after 60 to 90 days to determine whether oxygen is still indicated and is therapeutic.[1] Among different therapeutic modalities in COPD, the only two factors that improve survival are smoking cessation and oxygen supplementation.

Oxygen therapy helps to minimise pulmonary hypertension by decreasing pulmonary artery pressure, and improves exercise tolerance and quality of life. It has been shown to improve survival.[1] [46]

There is some evidence that oxygen can relieve breathlessness when given during exercise to mildly hypoxaemic and non-hypoxaemic people with COPD who do not otherwise qualify for home oxygen therapy.[190] The ATS suggests prescribing ambulatory oxygen (oxygen delivered during exercise or activities of daily living) in adults with COPD who have severe exertional room air hypoxaemia.[189]

However, the ATS suggests not prescribing long-term oxygen therapy in adults with COPD who have moderate chronic resting room air hypoxaemia (\( \text{SpO}_2 \) of 89%-93%).[189]

Air travel is safe for most patients receiving long-term oxygen therapy.[1] Patients with \( \text{SaO}_2 >95\% \) at sea level and \( \text{SaO}_2 \geq 84\% \) after a 6-minute walk test may travel by air without further assessment.[1] [191] Supplemental oxygen is recommended for patients with \( \text{SaO}_2 \) 92% to 95% at sea level and \( \text{SaO}_2 <84\% \) after a 6-minute walk test, and for patients with \( \text{SaO}_2 <92\% \) at sea level.[191] Hypoxia-altitude simulation testing should be performed for other patients.[191]
For patients who have COPD and obstructive sleep apnoea, ventilatory support with continuous positive airway pressure (CPAP) can improve survival and reduce hospital admissions.[1] [192] Non-invasive ventilation (NIV) is occasionally used in patients with very severe but stable COPD, although the optimal timing for initiation and best selection criteria for candidates is unclear.[1] [193] [194] A Cochrane review found that chronic NIV delivered via a facial mask improved survival and conferred short-term health-related quality of life benefit in stable COPD. Chronic NIV also improved duration of hospital admission-free survival in patients with persistent hypercapnia following an exacerbation.[194] Another study reported a significant decrease in exacerbation frequency with NIV versus control therapy, although no improvements were observed in mortality, PaO₂, PaCO₂, or pH.[195]

Guidelines from the American Thoracic Society suggest the use of nocturnal NIV in addition to usual care for patients with chronic stable hypercapnic COPD.[196] The European Respiratory Society and Canadian Thoracic Society have issued similar guidance.[197] [198]

Surgery

Surgical interventions (bullectomy, lung volume reduction surgery,[199] [200] and lung transplant) are the last step in the management of COPD. They are used to improve lung dynamics, exercise adherence, and quality of life.[200] Lung volume reduction surgery is indicated in patients with very severe airflow limitation, and especially in patients with localised upper lobe disease and lower than normal exercise capacity.[199] One meta-analysis found an increased risk of early mortality in patients who underwent lung volume reduction surgery compared to standard care; however, no significant difference was observed in overall mortality.[201] Bullectomy is an option in COPD patients with dyspnoea in whom CT reveals huge bullae occupying at least 30% of the hemithorax. Severely poor functional status and severe decrease in FEV1 (<500 mL) make these options less favourable. Endobronchial valve insertion can produce clinically meaningful improvements in appropriately selected patients with COPD.[202] [201] [203] The procedure may be most beneficial in patients whose dyspnoea is primarily due to hyperinflation and air trapping in the air spaces distal to the terminal bronchioles, which manifests as emphysema with markedly increased residual volume. Contraindications include active lung infection and incomplete lobar fissures (<80%).[204] The most common adverse events associated with endobronchial valve insertion are pneumothorax and exacerbation.[201]

Criteria for referral for lung transplantation include:[205]

- Body mass index, airflow Obstruction, Dyspnoea, and Exercise (BODE) score 5-6 with additional factor(s) present suggestive of increased risk of mortality:
  - Frequent acute exacerbations
  - Increase in BODE score >1 over past 24 months
  - Pulmonary artery to aorta diameter >1 on CT scan
  - FEV1 20% to 25% predicted.
- Clinical deterioration despite maximal treatment including medication, pulmonary rehabilitation, oxygen therapy, and, as appropriate, nocturnal non-invasive positive pressure ventilation
- Poor quality of life unacceptable to the patient
- For a patient who is a candidate for bronchoscopic or surgical lung volume reduction (LVR), simultaneous referral for both lung transplant and LVR evaluation is appropriate.

Lung transplantation has been shown to improve quality of life and functional capacity.[200] However, lung transplantation does not appear to confer a survival benefit.[206]
Palliative care

Palliative therapies to improve symptoms of dyspnoea, offer nutritional support, address anxiety and depression, and reduce fatigue may benefit patients with COPD who experience these despite optimal medical therapy.[1] End-of-life care and hospice admission should be considered for patients with very advanced disease. Patient and family should be well educated about the process, and it is suggested that discussions should be held early in the course of the disease before acute respiratory failure develops.[207] Opioid analgesics, fans, neuromuscular electrical stimulation, and chest wall vibration can relieve dyspnoea.[1] One study has suggested that low doses of an opioid analgesic and a benzodiazepine are safe and are not associated with increased hospital admissions or mortality.[208] Another study found that regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD and refractory breathlessness.[209]

One Cochrane review concluded that there is no evidence for or against benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD.[210]

Acupuncture and acupressure may also improve breathlessness and quality of life in patients with advanced COPD.[211]

Treatment algorithm overview

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
<table>
<thead>
<tr>
<th>Acute</th>
<th></th>
<th>(summary)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GOLD group A: initial treatment</strong></td>
<td>1st</td>
<td>short- or long-acting bronchodilator</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>supportive care and advice</td>
</tr>
<tr>
<td><strong>GOLD group B: initial treatment</strong></td>
<td>1st</td>
<td>LABA or LAMA</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>short-acting bronchodilator</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>supportive care and advice</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>pulmonary rehabilitation</td>
</tr>
<tr>
<td><strong>GOLD group C: initial treatment</strong></td>
<td>1st</td>
<td>LAMA</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>short-acting bronchodilator</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>supportive care and advice</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>pulmonary rehabilitation</td>
</tr>
<tr>
<td><strong>GOLD group D: initial treatment</strong></td>
<td>1st</td>
<td>LAMA or LABA/LAMA or LABA/ICS</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>short-acting bronchodilator</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>supportive care and advice</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>pulmonary rehabilitation</td>
</tr>
</tbody>
</table>
### Ongoing

<table>
<thead>
<tr>
<th>GOLD group A, B, C, or D: persistent dyspnoea/exercise limitation after initial therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
</tr>
<tr>
<td>plus</td>
</tr>
<tr>
<td>plus</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
</tbody>
</table>

### Ongoing

<table>
<thead>
<tr>
<th>GOLD group A, B, C, or D: persistent exacerbations after initial therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
</tr>
<tr>
<td>plus</td>
</tr>
<tr>
<td>plus</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
<tr>
<td>adjunct</td>
</tr>
</tbody>
</table>
Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer.
### Acute

**GOLD group A: initial treatment**

<table>
<thead>
<tr>
<th>1st short- or long-acting bronchodilator</th>
<th>Primary options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SABA</strong></td>
<td></td>
</tr>
<tr>
<td>» Salbutamol inhaled: (100 micrograms/dose inhaler) 100-200 micrograms (1-2 puffs) every 4-6 hours when required</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td><strong>SAMA</strong></td>
<td></td>
</tr>
<tr>
<td>» Ipratropium inhaled: (20 micrograms/dose inhaler) 40 micrograms (2 puffs) up to four times a day when required</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td><strong>LABA</strong></td>
<td></td>
</tr>
<tr>
<td>» Salmeterol inhaled: (50 micrograms/dose inhaler) 50 micrograms (1 puff) twice daily</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td><strong>LABA</strong></td>
<td></td>
</tr>
<tr>
<td>» Arformoterol inhaled: 15 micrograms nebulised twice daily</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td><strong>LABA</strong></td>
<td></td>
</tr>
<tr>
<td>» Olodaterol inhaled: (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td><strong>LAMA</strong></td>
<td></td>
</tr>
<tr>
<td>» Tiotropium inhaled: (18 micrograms/capsule inhaler) 18 micrograms (1 capsule) once daily; (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td><strong>LAMA</strong></td>
<td></td>
</tr>
<tr>
<td>» Umeclidinium inhaled: (62.5 micrograms/ dose inhaler) 62.5 micrograms (1 puff) once daily</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td><strong>LAMA</strong></td>
<td></td>
</tr>
</tbody>
</table>
Chronic obstructive pulmonary disease (COPD)

Management

Acute

» **acldinium bromide inhaled**: (400 micrograms/dose inhaler) 400 micrograms (1 puff) twice daily

**OR**

**LAMA**

» **glycopyrronium inhaled**: (55 micrograms/capsule inhaler) 55 micrograms (1 capsule) once daily

Each capsule delivers 55 micrograms of glycopyrronium bromide (equivalent to 44 micrograms of glycopyrronium).

» Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A patients are characterised by few symptoms and low risk of exacerbations.

» A short-acting bronchodilator or long-acting bronchodilator should be offered first line. Long-acting beta-2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are preferred over short-acting bronchodilators, except for patients with only occasional dyspnoea.[1] LABAs and LAMAs both significantly improve lung function, dyspnoea, and health status and reduce exacerbation rates. LAMAs have a greater effect on exacerbation reduction than LABAs.[60] [61]

» If a long-acting bronchodilator is prescribed, a short-acting bronchodilator should also be prescribed for rescue therapy. Regular use of short-acting bronchodilators is not generally recommended.

» Short-acting beta-2 agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) improve lung function and breathlessness and quality of life. Ipratropium, a SAMA, may have a small benefit over SABAs in improving health-related quality of life.[78]

» SAMAs should be discontinued if a LAMA is prescribed.

» SABAs include salbutamol. Ipratropium is a SAMA. LABAs include salmeterol, arformoterol, and olodaterol. LAMAs include tiotropium, umclidinium, aclidinium, and glycopyrronium.

plus **supportive care and advice**

Treatment recommended for ALL patients in selected patient group

» Smoking cessation should be encouraged in all patients, in addition to guidance on avoiding
Chronic obstructive pulmonary disease (COPD) Management

### Acute

exposure to occupational or environmental tobacco smoke and other irritants.[1][2]

Smoking cessation significantly reduces the rate of progression of COPD and risk of malignancies.

» Depending on local guidelines, patients should be vaccinated against influenza virus, *Streptococcus pneumoniae*, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19).[1][169] Vaccination against influenza is associated with fewer exacerbations of COPD.[170][171] The US Centers for Disease Control and Prevention (CDC) also recommends the tetanus/diphtheria/pertussis vaccine in people with COPD who were not vaccinated in adolescence, and varicella-zoster virus (shingles) for adults with COPD aged 50 years and over.[169]

» Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control.[144][145] Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.[147]

» All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. No medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications. Self-management education should include provision of a written action plan. Physical activity is recommended for all patients with COPD.[1]

<table>
<thead>
<tr>
<th>GOLD group B: initial treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1st</strong> &lt;br&gt; LABA or LAMA</td>
</tr>
<tr>
<td><strong>Primary options</strong></td>
</tr>
<tr>
<td>LABA</td>
</tr>
<tr>
<td>» salmeterol inhaled: (50 micrograms/dose inhaler) 50 micrograms (1 puff) twice daily</td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td>LABA</td>
</tr>
<tr>
<td>» arformoterol inhaled: 15 micrograms nebulised twice daily</td>
</tr>
</tbody>
</table>
**Acute**

**OR**

**LABA**

- **olodaterol inhaled:** (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily

**OR**

**LAMA**

- **tiotropium inhaled:** (18 micrograms/capsule inhaler) 18 micrograms (1 capsule) once daily; (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily

**OR**

**LAMA**

- **umeclidinium inhaled:** (62.5 micrograms/dose inhaler) 62.5 micrograms (1 puff) once daily

**OR**

**LAMA**

- **aclidinium bromide inhaled:** (400 micrograms/dose inhaler) 400 micrograms (1 puff) twice daily

**OR**

**LAMA**

- **glycopyrronium inhaled:** (55 micrograms/capsule inhaler) 55 micrograms (1 capsule) once daily

Each capsule delivers 55 micrograms of glycopyrronium bromide (equivalent to 44 micrograms of glycopyrronium).

**OR**

**LAMA**

- **revefenacin inhaled:** 175 micrograms nebulised once daily

**Global Initiative for Chronic Obstructive Lung Disease (GOLD) group B patients are characterised by more symptoms and low risk of exacerbations.**

**Either a long-acting muscarinic antagonist (LAMA) or a long-acting beta-2 agonist (LABA) may be prescribed. There is no evidence to recommend one class of long-acting bronchodilator over another for initial treatment in this group of patients. The choice should**
**Acute**

depend on the patient's perception of symptom relief.\[1\] LABAs and LAMAs both significantly improve lung function, dyspnoea, and health status and reduce exacerbation rates. For patients with severe breathlessness, initial treatment with two bronchodilators of different classes may be warranted.\[1\]

- LABAs include salmeterol, arformoterol, and olodaterol. LAMAs include tiotropium, umeclidinium, aclidinium, and glycopyrronium. Revefenacin is a nebulised LAMA approved for the maintenance treatment of moderate to severe COPD.

**plus** short-acting bronchodilator

Treatment recommended for ALL patients in selected patient group

**Primary options**

- salbutamol inhaled: (100 micrograms/dose inhaler) 100-200 micrograms (1-2 puffs) every 4-6 hours when required

**OR**

- ipratropium inhaled: (20 micrograms/dose inhaler) 40 micrograms (2 puffs) up to four times a day when required

- All patients diagnosed with COPD should be prescribed a short-acting bronchodilator for immediate symptom relief.\[1\] Short-acting beta-2 agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) improve lung function and breathlessness and quality of life.

- Ipratropium, a SAMA, may have a small benefit over SABAs in improving health-related quality of life.\[78\] SAMAs should be discontinued if a LAMA is prescribed. SABAs include salbutamol.

**plus** supportive care and advice

Treatment recommended for ALL patients in selected patient group

- Smoking cessation should be encouraged in all patients, in addition to guidance on avoiding exposure to occupational or environmental tobacco smoke or other irritants.\[1\] \[2\] Smoking cessation significantly reduces the rate of progression of COPD and risk of malignancies.
Chronic obstructive pulmonary disease (COPD)

Management

Acute

» Depending on local guidelines, patients should be vaccinated against influenza virus, Streptococcus pneumoniae, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19).[1] [169] Vaccination against influenza is associated with fewer exacerbations of COPD.[170] [171] The US Centers for Disease Control and Prevention (CDC) also recommends the tetanus/diphtheria/pertussis vaccine in people with COPD who were not vaccinated in adolescence, and varicella-zoster virus (shingles) for adults with COPD aged 50 years and over.[169]

» Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control.[144] [145] Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.[147]

» All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. No medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications. Self-management education should include provision of a written action plan. Physical activity is recommended for all patients with COPD.[1]

plus pulmonary rehabilitation

Treatment recommended for ALL patients in selected patient group

» Pulmonary rehabilitation compromises aerobic exercise, strength training, and education, and should be started early in the disease course. GOLD guidelines recommend pulmonary rehabilitation for patient groups B to D.[1]

» Pulmonary rehabilitation relieves dyspnoea and fatigue, improves emotional function, and enhances a sense of control to a moderately large and clinically significant extent.[176]

» A large US cohort study found that initiation of pulmonary rehabilitation within 90 days of hospital discharge following an acute exacerbation of COPD was significantly associated with lower mortality risk at 1 year and fewer rehospitalisations at 1 year.[212]
### Acute

[180] However, starting pulmonary rehabilitation before hospital discharge could be associated with a higher 12-month mortality, so is not recommended.[181]

<table>
<thead>
<tr>
<th>GOLD group C: Initial treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
</tr>
<tr>
<td><strong>Primary options</strong></td>
</tr>
<tr>
<td>» tiotropium inhaled: (18 micrograms/capsule inhaler) 18 micrograms (1 capsule) once daily; (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily OR</td>
</tr>
<tr>
<td>» umeclidinium inhaled: (62.5 micrograms/dose inhaler) 62.5 micrograms (1 puff) once daily OR</td>
</tr>
<tr>
<td>» aclidinium bromide inhaled: (400 micrograms/dose inhaler) 400 micrograms (1 puff) twice daily OR</td>
</tr>
<tr>
<td>» glycopyrronium inhaled: (55 micrograms/capsule inhaler) 55 micrograms (1 capsule) once daily Each capsule delivers 55 micrograms of glycopyrronium bromide (equivalent to 44 micrograms of glycopyrronium). OR</td>
</tr>
<tr>
<td>» revefenacin inhaled: 175 micrograms nebulised once daily</td>
</tr>
</tbody>
</table>

Global Initiative for Chronic Obstructive Lung Disease (GOLD) Group C patients have few symptoms and a higher risk of exacerbations.

» GOLD recommends starting a long-acting muscarinic antagonist (LAMA) in this group.[1] LAMAs have a greater effect on exacerbation reduction than long-acting beta-2 agonists (LABAs) in patients with moderate to very severe COPD.[60] [61]

**plus short-acting bronchodilator**

Treatment recommended for ALL patients in selected patient group.
Chronic obstructive pulmonary disease (COPD)

Management

### Acute

#### Primary options

- **salbutamol inhaled**: (100 micrograms/dose inhaler) 100-200 micrograms (1-2 puffs) every 4-6 hours when required

- All patients diagnosed with COPD should be prescribed a short-acting bronchodilator for immediate symptom relief.[1] Short-acting beta-2 agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) improve lung function and breathlessness and quality of life.[78]

- Ipratropium, a SAMA, may have a small benefit over SABAs in improving health-related quality of life.[78] SAMAs should not be prescribed with a LAMA. SABAs include salbutamol.

- Regular use of short-acting bronchodilators is not generally recommended. Failure to respond to short-acting bronchodilator may signify an acute exacerbation.

#### plus supportive care and advice

Treatment recommended for ALL patients in selected patient group

- Smoking cessation should be encouraged in all patients, in addition to guidance on avoiding exposure to occupational or environmental tobacco smoke or other irritants.[1] [2] Smoking cessation significantly reduces the rate of progression of COPD and risk of malignancies.

- Depending on local guidelines, patients should be vaccinated against influenza virus, *Streptococcus pneumoniae*, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19).[1] [169] Vaccination against influenza is associated with fewer exacerbations of COPD.[170] [171] The US Centers for Disease Control and Prevention (CDC) also recommends the tetanus/diphtheria/pertussis vaccine in people with COPD who were not vaccinated in adolescence, and varicella-zoster virus (shingles) for adults with COPD aged 50 years and over.[169]

- Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control.[144] [145] Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.[147]
Acute

» All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. No medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications. Self-management education should include provision of a written action plan. Physical activity is recommended for all patients with COPD.[1]

plus pulmonary rehabilitation

Treatment recommended for ALL patients in selected patient group

» Pulmonary rehabilitation compromises aerobic exercise, strength training, and education, and should be started early in the disease course. GOLD guidelines recommend pulmonary rehabilitation for patient groups B to D.[1]

» Pulmonary rehabilitation relieves dyspnoea and fatigue, improves emotional function, and enhances a sense of control to a moderately large and clinically significant extent.[176]

» A large US cohort study found that initiation of pulmonary rehabilitation within 90 days of hospital discharge following an acute exacerbation of COPD was significantly associated with lower mortality risk at 1 year and fewer rehospitalisations at 1 year.[212] [180] However, starting pulmonary rehabilitation before hospital discharge could be associated with a higher 12-month mortality, so is not recommended.[181]

GOLD group D: initial treatment

1st LAMA or LABA/LAMA or LABA/ICS

Primary options

LAMA

» tiotropium inhaled: (18 micrograms/capsule inhaler) 18 micrograms (1 capsule) once daily; (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily

OR

LAMA

» umeclidinium inhaled: (62.5 micrograms/ dose inhaler) 62.5 micrograms (1 puff) once daily

OR
### Acute

<table>
<thead>
<tr>
<th>LAMA</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>» aclidinium bromide inhaled: (400 micrograms/dose inhaler) 400 micrograms (1 puff) twice daily</td>
<td>OR</td>
</tr>
<tr>
<td>» glycopyrronium inhaled: (55 micrograms/capsule inhaler) 55 micrograms (1 capsule) once daily</td>
<td>OR</td>
</tr>
<tr>
<td>Each capsule delivers 55 micrograms of glycopyrronium bromide (equivalent to 44 micrograms of glycopyrronium).</td>
<td>OR</td>
</tr>
<tr>
<td>» revefenacin inhaled: 175 micrograms nebulised once daily</td>
<td>OR</td>
</tr>
<tr>
<td>» umeclidinium/vilanterol inhaled: (62.5/25 micrograms/dose inhaler) 1 puff once daily</td>
<td>OR</td>
</tr>
<tr>
<td>» glycopyrronium/formoterol fumarate inhaled: (14.4/9.6 micrograms/dose inhaler) 1 puff twice daily</td>
<td>OR</td>
</tr>
<tr>
<td>» tiotropium/olodaterol inhaled: (2.5/2.5 micrograms/dose inhaler) 2 puffs once daily</td>
<td>OR</td>
</tr>
<tr>
<td>» aclidinium bromide/formoterol fumarate inhaled: (400/12 micrograms/dose inhaler) 1 puff twice daily</td>
<td>OR</td>
</tr>
<tr>
<td>» fluticasone furoate/vilanterol inhaled: (100/25 micrograms/dose inhaler) 1 puff once daily</td>
<td>OR</td>
</tr>
</tbody>
</table>
## Acute

<table>
<thead>
<tr>
<th>LABA/ICS</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>fluticasone propionate/salmeterol inhaled:</strong> (250/50 micrograms/dose inhaler) 1 puff twice daily</td>
<td>OR</td>
</tr>
<tr>
<td><strong>budesonide/formoterol inhaled:</strong> (160/4.5 micrograms/dose inhaler) 2 puffs twice daily</td>
<td>OR</td>
</tr>
<tr>
<td><strong>mometasone/formoterol inhaled:</strong> (100/5 micrograms/dose inhaler; 200/5 micrograms/dose inhaler) 2 puffs twice daily</td>
<td>OR</td>
</tr>
</tbody>
</table>

- Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D patients are characterised by more symptoms and high risk of exacerbations.

- GOLD recommends starting therapy with a long-acting muscarinic antagonist (LAMA), a long-acting beta-2 agonist (LABA)/LAMA combination, or an inhaled corticosteroid (ICS)/LABA combination. [1]

- LAMA is the first choice for most patients. A LABA/LAMA combination should be considered if the patient is highly symptomatic (COPD assessment test [CAT] score >20), especially if the patient has significant dyspnoea and/or exercise limitation. [1]

- An ICS/LABA combination should be considered if the patient’s blood eosinophil count is \( \geq 300 \) cells/microlitre or the patient has a history of asthma. [1] The effect of treatment regimens containing ICS is higher in patients at higher risk of exacerbations (two or more exacerbations and/or one hospitalisation for an exacerbation in the previous year). [69] [71] [98] Blood eosinophil count may predict the effectiveness of adding inhaled corticosteroids to regular long-acting bronchodilator treatment to prevent exacerbations. [99] [64] [65] Little or no effect is seen at blood eosinophil counts of <100 cells/microlitre, while maximal effect is seen at blood eosinophil counts of >300 cells/microlitre. [63] [74] These thresholds indicate approximate cut-off values which may help clinicians predict the likelihood of a treatment.
Chronic obstructive pulmonary disease (COPD)

Management

Acute benefit.[1] Use of ICS also slows the rate of decline in lung function following an exacerbation in patients with mild to moderate COPD and elevated blood eosinophils.[117] Former smokers are more corticosteroid-responsive than current smokers at any eosinophil count.[99] Both current and former smokers with COPD can benefit from ICS in terms of lung function and rates of exacerbations, although the effect is smaller for heavy or current smokers compared with light or former smokers.[71][100]

» Combination therapy with an inhaled corticosteroid and a LABA is superior to use of either agent alone.[115][116] ICS increases the risk of developing pneumonia in some patients, so should only be used as initial therapy after the possible clinical risks and benefits have been evaluated.

» LAMAs include tiotropium, umeclidinium, aclidinium, and glycopyrronium. Umeclidinium/vilanterol, glycopyrronium/formoterol, tiotropium/olodaterol, and aclidinium/formoterol are LABA/LAMA combinations approved for use in COPD.[213][98] Umeclidinium/vilanterol decreases the risk of exacerbations in patients with mild/moderate COPD.[92] LABA/ICS combinations include fluticasone furoate/vilanterol, fluticasone propionate/salmeterol, budesonide/formoterol, and mometasone/formoterol.

plus short-acting bronchodilator

Treatment recommended for ALL patients in selected patient group

Primary options

» salbutamol inhaled: (100 micrograms/dose inhaler) 100-200 micrograms (1-2 puffs) every 4-6 hours when required

OR

» ipratropium inhaled: (20 micrograms/dose inhaler) 40 micrograms (2 puffs) up to four times a day when required

» All patients diagnosed with COPD should be prescribed a short-acting bronchodilator for immediate symptom relief.[1] Short-acting beta-2 agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) improve lung function and breathlessness and quality of life.[78]

» Ipratropium, a SAMA, may have a small benefit over SABAs in improving health-related quality
Acute

- SAMAs should be discontinued if a LAMA is prescribed. SABAs include salbutamol.
- Regular use of short-acting bronchodilators is not generally recommended. Failure to respond to short-acting bronchodilator may signify an acute exacerbation.

**plus** supportive care and advice

Treatment recommended for ALL patients in selected patient group

- Smoking cessation should be encouraged in all patients, in addition to guidance on avoiding exposure to occupational or environmental tobacco smoke or other irritants. Smoking cessation significantly reduces the rate of progression of COPD and risk of malignancies.

- Depending on local guidelines, patients should be vaccinated against influenza virus, *Streptococcus pneumoniae*, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19). Vaccination against influenza is associated with fewer exacerbations of COPD. The US Centers for Disease Control and Prevention (CDC) also recommends the tetanus/diphtheria/pertussis vaccine in people with COPD who were not vaccinated in adolescence, and varicella-zoster virus (shingles) for adults with COPD aged 50 years and over.

- Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control. Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.

- All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. No medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications. Self-management education should include provision of a written action plan. Physical activity is recommended for all patients with COPD.

**plus** pulmonary rehabilitation
Chronic obstructive pulmonary disease (COPD) Management

**Acute**

Treatment recommended for ALL patients in selected patient group

- Pulmonary rehabilitation compromises aerobic exercise, strength training, and education, and should be started early in the disease course. GOLD guidelines recommend pulmonary rehabilitation for patient groups B to D.[1]

- Pulmonary rehabilitation relieves dyspnoea and fatigue, improves emotional function, and enhances a sense of control to a moderately large and clinically significant extent.[176]

- A large US cohort study found that initiation of pulmonary rehabilitation within 90 days of hospital discharge following an acute exacerbation of COPD was significantly associated with lower mortality risk at 1 year and fewer rehospitalisations at 1 year.[212][180] However, starting pulmonary rehabilitation before hospital discharge could be associated with a higher 12-month mortality, so is not recommended.[181]
**Chronic obstructive pulmonary disease (COPD)**

**Management**

### Ongoing

<table>
<thead>
<tr>
<th><strong>GOLD group A, B, C, or D: persistent dyspnoea/exercise limitation after initial therapy</strong></th>
</tr>
</thead>
</table>

1st **LABA/LAMA or LABA/LAMA/ICS**

**Primary options**

**LABA/LAMA**

- **umeclidinium/vilanterol inhaled:** (62.5/25 micrograms/dose inhaler) 1 puff once daily

  OR

- **LABA/LAMA**

  - **glycopyrronium/formoterol fumarate inhaled:** (14.4/9.6 micrograms/dose inhaler) 1 puff twice daily

  OR

- **LABA/LAMA**

  - **tiotropium/olodaterol inhaled:** (2.5/2.5 micrograms/dose inhaler) 2 puffs once daily

  OR

- **LABA/LAMA**

  - **aclidinium bromide/formoterol fumarate inhaled:** (400/12 micrograms/dose inhaler) 1 puff twice daily

  OR

- **LABA/LAMA/ICS**

  - **fluticasone furoate/umeclidinium/vilanterol inhaled:** (92/55/22 micrograms/dose inhaler) 1 puff once daily

    Each single inhalation provides a delivered dose of 92 micrograms of fluticasone furoate, 65 micrograms of umeclidinium bromide (equivalent to 55 micrograms of umeclidinium), and 22 micrograms of vilanterol (as trifenateate).

  OR

- **LABA/LAMA/ICS**

  - **fluticasone furoate/vilanterol inhaled:** (100/25 micrograms/dose inhaler) 1 puff once daily

    OR

  - **fluticasone propionate/salmeterol inhaled:** (250/50 micrograms/dose inhaler) 1 puff twice daily
Chronic obstructive pulmonary disease (COPD) Management

Ongoing

- or -
» budesonide/formoterol inhaled: (160/4.5 micrograms/dose inhaler) 2 puffs twice daily
- or -
» mometasone/formoterol inhaled: (100/5 micrograms/dose inhaler; 200/5 micrograms/dose inhaler) 2 puffs twice daily
-- AND --
» tiotropium inhaled: (18 micrograms/capsule inhaler) 18 micrograms (1 capsule) once daily; (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily
- or -
» umeclidinium inhaled: (62.5 micrograms/dose inhaler) 62.5 micrograms (1 puff) once daily
- or -
» aclidinium bromide inhaled: (400 micrograms/dose inhaler) 400 micrograms (1 puff) twice daily
- or -
» glycopyrouronium inhaled: (55 micrograms/capsule inhaler) 55 micrograms (1 capsule) once daily

Each capsule delivers 55 micrograms of glycopyrouronium bromide (equivalent to 44 micrograms of glycopyrouronium).

- Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A patients are characterised by few symptoms and low risk of exacerbations; group B by more symptoms and low risk of exacerbations; group C by few symptoms and a higher risk of exacerbations; and group D by more symptoms and high risk of exacerbations.[1]

- GOLD advise that if a patient has both persistent symptoms and exacerbations after initial therapy, clinicians should follow the pathway for treating persistent exacerbations.[1]

- Patients with persistent dyspnoea/exercise limitation while on a long-acting beta-2 agonist (LABA) or a long-acting muscarinic antagonist (LAMA) alone should switch to dual long-acting bronchodilator therapy with a LABA/LAMA combination. If symptoms do not improve, the second long-acting bronchodilator should be stopped. Changing inhaler device or molecules may be considered.[1] A LABA/LAMA combination may provide a better therapeutic effect without increasing the adverse effects of each class.[86] [88] [89] [90] Combination therapy with a LABA/LAMA reduces exacerbation rate compared with monotherapy. Once-daily LABA/LAMA delivered
Chronic obstructive pulmonary disease (COPD)

**Management**

<table>
<thead>
<tr>
<th>Ongoing</th>
</tr>
</thead>
<tbody>
<tr>
<td>via a combination inhaler is more associated with a clinically significant improvement in lung function and health-related quality of life in patients with mild/moderate COPD, compared with placebo.[92]</td>
</tr>
</tbody>
</table>

» Patients with persistent dyspnoea/exercise limitation while on combined LABA and inhaled corticosteroid (ICS) therapy may switch to LABA/LAMA/ICS. The indication for ICS should be reviewed. If the original indication was not appropriate, or if the patient has not responded to ICS treatment or experienced significant adverse effects, ICS should be withdrawn and the patient switched to a LABA/LAMA.[1] The combination may be provided in separate inhalers or a combination inhaler.

» Dyspnoea due to other causes should be considered, investigated, and treated. Inhaler technique and adherence should also be re-assessed, as these may have led to an inadequate response to treatment.

**plus** short-acting bronchodilator

Treatment recommended for ALL patients in selected patient group

**Primary options**

| » salbutamol inhaled: (100 micrograms/dose inhaler) 100-200 micrograms (1-2 puffs) every 4-6 hours when required |

» All patients diagnosed with COPD should be prescribed a short-acting bronchodilator for immediate symptom relief.[1]

» Short-acting beta-2 agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) improve lung function and breathlessness and quality of life.[78]

» Regular use of short-acting bronchodilators is not generally recommended. Failure to respond to short-acting bronchodilator may signify an acute exacerbation.

» SAMAs should not be prescribed with a LAMA. SABAs include salbutamol.

**plus** supportive care and advice

Treatment recommended for ALL patients in selected patient group

» Smoking cessation should be encouraged in all patients, in addition to guidance on avoiding exposure to occupational or environmental tobacco smoke or other irritants.[1] [2] Smoking...
Ongoing cessation significantly reduces the rate of progression of COPD and risk of malignancies.

» Depending on local guidelines, patients should be vaccinated against influenza virus, *Streptococcus pneumoniae*, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19).[1] [169] Vaccination against influenza is associated with fewer exacerbations of COPD.[170] [171] The US Centers for Disease Control and Prevention (CDC) also recommends the tetanus/diphtheria/pertussis vaccine in people with COPD who were not vaccinated in adolescence, and varicella-zoster virus (shingles) for adults with COPD aged 50 years and over.[169]

» Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control.[144] [145] Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.[147]

» All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. No medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications. Self-management education should include provision of a written action plan. Physical activity is recommended for all patients with COPD.[1]

adjunct pulmonary rehabilitation

Treatment recommended for SOME patients in selected patient group

» Pulmonary rehabilitation compromises aerobic exercise, strength training, and education, and should be started early in the disease course. GOLD guidelines recommend pulmonary rehabilitation for patient groups B to D.[1]

» Pulmonary rehabilitation relieves dyspnoea and fatigue, improves emotional function, and enhances a sense of control to a moderately large and clinically significant extent.[176]

» A large US cohort study found that initiation of pulmonary rehabilitation within 90 days of hospital discharge following an acute
exacerbation of COPD was significantly associated with lower mortality risk at 1 year and fewer rehospitalisations at 1 year.[212][180] However, starting pulmonary rehabilitation before hospital discharge could be associated with a higher 12-month mortality, so is not recommended.[181]

adjunct oxygen therapy and/or ventilatory support

Treatment recommended for SOME patients in selected patient group

» GOLD guidelines recommend long-term oxygen therapy in stable patients who have: PaO₂ ≤7.3 kPa (55 mmHg) or SaO₂ <88%, with or without hypercapnia confirmed twice over a 3-week period; or PaO₂ between 7.3 kPa (55 mmHg) and 8.0 kPa (60 mmHg) or SaO₂ of 88%, if there is evidence of pulmonary hypertension, peripheral oedema suggesting congestive cardiac failure, or polycythaemia (haematocrit >55%).[1]

» Guidelines from the American Thoracic Society (ATS) recommend prescribing long-term oxygen therapy for at least 15 hours per day in adults with COPD who have severe chronic resting room air hypoxaemia. The ATS defines severe hypoxaemia as either: PaO₂ ≤7.3 kPa (55 mmHg) or oxygen saturation as measured by pulse oximetry (SpO₂) ≤88%; or PaO₂ 7.5-7.9 kPa (56-59 mmHg) or SpO₂ of 89% plus one of the following: oedema, haematocrit ≥55%, or P pulmonale on an ECG.[189]

» For patients prescribed home oxygen therapy, the ATS recommends that the patient and their caregivers should receive instruction and training on the use and maintenance of all oxygen equipment and education on oxygen safety, including smoking cessation, fire prevention, and tripping hazards.[189]

» Supplemental oxygen should be titrated to achieve SaO₂ ≥90%. [1] The patient should be reassessed after 60 to 90 days to determine whether oxygen is still indicated and is therapeutic. [1] Among different therapeutic modalities in COPD, the only two factors that improve survival are smoking cessation and oxygen supplementation.

» Oxygen therapy helps to minimise pulmonary hypertension by decreasing pulmonary artery pressure, and improves exercise tolerance and quality of life. It has been shown to improve survival.[1] [46]
The ATS suggests prescribing ambulatory oxygen (oxygen delivered during exercise or activities of daily living) in adults with COPD who have severe exertional room air hypoxaemia.\(^{[189]}\) However, the ATS suggests not prescribing long-term oxygen therapy in adults with COPD who have moderate chronic resting room air hypoxaemia (SpO₂ of 89%-93%).\(^{[189]}\)

For patients who have COPD and obstructive sleep apnoea, ventilatory support with continuous positive airway pressure (CPAP) can improve survival and reduce hospital admissions.\(^{[1]}\)\(^{[192]}\) Non-invasive ventilation is occasionally used in patients with very severe but stable COPD, although the best selection criteria for candidates is unclear.\(^{[1]}\)\(^{[193]}\)

Guidelines from the American Thoracic Society suggest the use of nocturnal NIV in addition to usual care for patients with chronic stable hypercapnic COPD.\(^{[196]}\) The European Respiratory Society and Canadian Thoracic Society have issued similar guidance.\(^{[197]}\)\(^{[198]}\)

### Primary options

- **adjunct mucolytic**

  Treatment recommended for SOME patients in selected patient group

**Primary options**

- **erdosteine**: consult specialist for guidance on dose

  OR

- **acetylcysteine**: consult specialist for guidance on dose

  OR

- **carbocisteine**: consult specialist for guidance on dose

Patients with the chronic bronchitis phenotype of COPD often produce thick sputum on a frequent basis. Mucolytic agents result in a small reduction in the frequency of acute exacerbations and in days of disability per month, but do not improve lung function or quality of life.\(^{[173]}\) One meta-analysis comparing erdosteine, carbocisteine, and acetylcysteine concluded that erdosteine had the most favourable safety and efficacy profile. Erdosteine reduced the risk of hospitalisation due to an acute exacerbation, and erdosteine...
**Management**

### Ongoing

and acetylcysteine reduced the duration of an acute exacerbation.[174] Erdosteine is therefore the preferred option in countries where it is available. Another meta-analysis found that acetylcysteine significantly reduced the frequency of exacerbations compared with placebo, without increasing the risk of adverse effects. The authors concluded that 3 months of treatment with a low dosage was effective.[175] Treatment with mucolytic agents such as carbocisteine and acetylcysteine may reduce exacerbations and modestly improve health status in patients not receiving ICS.[1]

Erdosteine may have a significant effect on mild exacerbations whether or not the patient is taking inhaled corticosteroids.[1]

### Adjunct Theophylline

<table>
<thead>
<tr>
<th>Treatment recommended for SOME patients in selected patient group</th>
</tr>
</thead>
</table>

**Primary options**

- **Theophylline**: consult specialist for guidance on dose

Theophylline (a methylxanthine agent) is not commonly used because of limited potency, narrow therapeutic window, high risk profile, and frequent drug-drug interactions. Theophylline is indicated for persistent symptoms if inhaled therapy is insufficient to relieve airflow obstruction. Theophylline has modest effects on lung function in moderate to severe COPD.[133] A large randomised controlled trial found no effect of oral theophylline alone or with prednisolone on exacerbations of severe COPD.[134] GOLD advise that theophylline should only be used if other long-term bronchodilator treatments are unavailable or unaffordable.[1] Experts may prescribe theophylline after a patient has exhausted all options for inhaled therapies. Toxicity is dose-related.

### Adjunct Bronchoscopic intervention or surgery

| Treatment recommended for SOME patients in selected patient group |

- Surgical interventions (bullectomy, lung volume reduction surgery,[199] [200] and lung transplant) are the last step in the management of COPD. They are used to improve lung dynamics, exercise adherence, and quality of life.[200] Lung volume reduction surgery is indicated in patients with very severe airflow limitation, and especially in patients with localised upper lobe disease and lower than...
normal exercise capacity.[199] One meta-analysis found an increased risk of early mortality in patients who underwent lung volume reduction surgery compared to standard care, however; no significant difference was observed in overall mortality.[201] Bullectomy is an option in COPD patients with dyspnoea in whom CT reveals huge bullae occupying at least 30% of the hemithorax. Severely poor functional status and severe decrease in FEV1 (<500 mL) make these options less favourable. Endobronchial valve insertion can produce clinically meaningful improvements in appropriately selected patients with COPD.[202] The procedure may be most beneficial in patients whose dyspnoea is primarily due to hyperinflation and air trapping in the air spaces distal to the terminal bronchioles, which manifests as emphysema with markedly increased residual volume. Contraindications include active lung infection and incomplete lobar fissures (<80%).[204] The most common adverse events associated with endobronchial valve insertion are pneumothorax and exacerbation.[201]

- Criteria for referral for lung transplantation include:[205]

- Body mass index, airflow Obstruction, Dyspnoea, and Exercise (BODE) score 5-6 with additional factor(s) present suggestive of increased risk of mortality: frequent acute exacerbations, increase in BODE score >1 over past 24 months, pulmonary artery to aorta diameter >1 on CT scan, and/or FEV1 20% to 25% predicted.

- Clinical deterioration despite maximal treatment including medication, pulmonary rehabilitation, oxygen therapy, and, as appropriate, nocturnal non-invasive positive pressure ventilation.

- Poor quality of life unacceptable to the patient.

- For a patient who is a candidate for bronchoscopic or surgical lung volume reduction (LVR), simultaneous referral for both lung transplant and LVR evaluation is appropriate.

- Lung transplantation has been shown to improve quality of life and functional capacity.[200] However, lung transplantation does not appear to confer a survival benefit.[206]
Chronic obstructive pulmonary disease (COPD)

**Ongoing**

Treatment recommended for SOME patients in selected patient group

» Palliative therapies to improve symptoms of dyspnoea, offer nutritional support, address anxiety and depression, and reduce fatigue may benefit patients with COPD who experience these despite optimal medical therapy.[1] End-of-life care and hospice admission should be considered for patients with very advanced disease. Patient and family should be well educated about the process, and it is suggested that discussions should be held early in the course of the disease before acute respiratory failure develops.[207] Opioid analgesics, fans, neuromuscular electrical stimulation, and chest wall vibration can relieve dyspnoea.[1] One study has suggested that low doses of an opioid analgesic and a benzodiazepine are safe and are not associated with increased hospital admissions or mortality.[208] Another study found that regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD and refractory breathlessness.[209]

» One Cochrane review concluded that there is no evidence for or against benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD.[210]

» Acupuncture and acupressure may also improve breathlessness and quality of life in patients with advanced COPD.[211]

**GOLD group A, B, C, or D: persistent exacerbations after initial therapy**

<table>
<thead>
<tr>
<th>1st</th>
<th>LABA/LAMA or LABA/ICS or LABA/LAMA/ICS</th>
</tr>
</thead>
</table>

**Primary options**

LABA/LAMA

» **umeclidinium/vilanterol inhaled**: (62.5/25 micrograms/dose inhaler) 1 puff once daily

OR

LABA/LAMA

» **glycopyrronium/formoterol fumarate inhaled**: (14.4/9.6 micrograms/dose inhaler) 1 puff twice daily

OR

LABA/LAMA
Chronic obstructive pulmonary disease (COPD) Management

Ongoing

» tiotropium/olodaterol inhaled: (2.5/2.5 micrograms/dose inhaler) 2 puffs once daily

OR

LABA/LAMA

» aclidinium bromide/formoterol fumarate inhaled: (400/12 micrograms/dose inhaler) 1 puff twice daily

OR

LABA/ICS

» fluticasone furoate/vilanterol inhaled: (100/25 micrograms/dose inhaler) 1 puff once daily

OR

LABA/ICS

» fluticasone propionate/salmeterol inhaled: (250/50 micrograms/dose inhaler) 1 puff twice daily

OR

LABA/ICS

» budesonide/formoterol inhaled: (160/4.5 micrograms/dose inhaler) 2 puffs twice daily

OR

LABA/ICS

» mometasone/formoterol inhaled: (100/5 micrograms/dose inhaler; 200/5 micrograms/dose inhaler) 2 puffs twice daily

OR

LABA/LAMA/ICS

» fluticasone furoate/umeclidinium/vilanterol inhaled: (92/55/22 micrograms/dose inhaler) 1 puff once daily

Each single inhalation provides a delivered dose of 92 micrograms of fluticasone furoate, 65 micrograms of umeclidinium bromide (equivalent to 55 micrograms of umeclidinium), and 22 micrograms of vilanterol (as trifenatate).
**Chronic obstructive pulmonary disease (COPD) Management**

### Ongoing

- **» fluticasone furoate/vilanterol inhaled:** (100/25 micrograms/dose inhaler) 1 puff once daily
- **-or-**
- **» fluticasone propionate/salmeterol inhaled:** (250/50 micrograms/dose inhaler) 1 puff twice daily
- **-or-**
- **» budesonide/formoterol inhaled:** (160/4.5 micrograms/dose inhaler) 2 puffs twice daily
- **-or-**
- **» mometasone/formoterol inhaled:** (100/5 micrograms/dose inhaler; 200/5 micrograms/dose inhaler) 2 puffs twice daily

---

- **AND—**
- **» tiotropium inhaled:** (18 micrograms/capsule inhaler) 18 micrograms (1 capsule) once daily; (2.5 micrograms/dose inhaler) 5 micrograms (2 sprays) once daily
- **-or-**
- **» umeclidinium inhaled:** (62.5 micrograms/dose inhaler) 62.5 micrograms (1 puff) once daily
- **-or-**
- **» aclidinium bromide inhaled:** (400 micrograms/dose inhaler) 400 micrograms (1 puff) twice daily
- **-or-**
- **» glycopyrronium inhaled:** (55 micrograms/capsule inhaler) 55 micrograms (1 capsule) once daily

Each capsule delivers 55 micrograms of glycopyrronium bromide (equivalent to 44 micrograms of glycopyrronium).

**Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A patients are characterised by few symptoms and low risk of exacerbations; group B by more symptoms and low risk of exacerbations; group C by few symptoms and a higher risk of exacerbations; and group D by more symptoms and high risk of exacerbations.**[1]

- Patients taking a long-acting beta-2 agonist (LABA) or long-acting muscarinic antagonist (LAMA) alone and who experience persistent exacerbations should increase therapy to either LABA/LAMA or LABA/inhaled corticosteroid (ICS).

- Blood eosinophil counts can identify patients who are more likely to respond to ICS.[63] [64] [65] LABA/ICS may be considered in patients with two or more moderate exacerbations per year, or at least one severe exacerbation needing hospital admission in the previous year,
and an eosinophil count ≥100 cells/microlitre, or if the history/clinical findings are suggestive of asthma.[1] Patients who have one exacerbation per year are more likely to respond to LABA/ICS if their peripheral eosinophil count is ≥300 cells/microlitre.[66] Use of ICS also slows the rate of decline in lung function following an exacerbation in patients with mild to moderate COPD and elevated blood eosinophils.[117] Former smokers are more corticosteroid-responsive than current smokers at any eosinophil count.[99]

 Patients on LABA or LAMA who experience persistent exacerbations and who have blood eosinophils <100 cells/microlitre or who have contraindications to ICS should commence a LABA/LAMA.[1]

 Patients who take LABA/LAMA who experience persistent exacerbations and whose blood eosinophils are ≥100 cells/microlitre should escalate to LABA/LAMA/ICS.[1] Multiple studies support triple therapy with LABA/LAMA/ICS as being superior to single- or double-agent therapy with LABA/LAMA or LABA/ICS regarding rate of moderate to severe COPD exacerbations and rate of hospitalisation.[67] [68] [69] [70] [71] [72] [73] [74] [75] One randomised controlled trial has reported a reduction in all-cause mortality in patients at risk of exacerbations who take fluticasone furoate/umeclidinium/vilanterol, compared with umeclidinium/vilanterol.[118] Another randomised controlled trial had similar findings in terms of mortality in the triple therapy arm (budesonide/glycopyrronium/formoterol), but only at the higher dose of ICS.[75] [119] For both studies, there were no differences in mortality compared with LABA/ICS.[75] [118] [119] A post hoc pooled analysis of three trials of triple therapy in patients with COPD and severe airflow limitation and a history of exacerbations showed a non-significant trend for lower mortality with triple therapy compared with non-ICS treatments.[120] These results are strengthened by findings from a meta-analysis of over 200 studies: triple therapy provided a significant reduction in mortality versus dual therapy, although was associated with greater risk of pneumonia. No differences were observed between regimens in lung function or health-related quality of life.[121]

 American Thoracic Society guidelines recommend the use of LABA/LAMA/ICS in patients who have had one or more exacerbations requiring oral corticosteroids, antibiotics, or hospitalisation in the past year and
Ongoing who have symptoms of dyspnoea or reduced exercise tolerance despite LABA/LAMA dual therapy.[76] UK guidelines recommend the use of LABA/LAMA/ICS in patients who have an exacerbation requiring hospitalisation, or two moderate exacerbations within a year, despite dual therapy with LABA/LAMA.[2]

» Patients who take LABA/ICS and who experience persistent exacerbations should switch to LABA/LAMA/ICS.[1] If ICS is ineffective or causing significant adverse effects, patients may switch to LABA/LAMA. Patients with blood eosinophils ≥300 cells/microlitre are at greatest risk of exacerbations after withdrawing ICS.[77]

plus short-acting bronchodilator

Treatment recommended for ALL patients in selected patient group

Primary options

» salbutamol inhaled: (100 micrograms/dose inhaler) 100-200 micrograms (1-2 puffs) every 4-6 hours when required

OR

» ipratropium inhaled: (20 micrograms/dose inhaler) 40 micrograms (2 puffs) up to four times a day when required

» All patients diagnosed with COPD should be prescribed a short-acting bronchodilator for immediate symptom relief.[1]

» Short-acting beta-2 agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) improve lung function and breathlessness and quality of life.[78] Ipratropium, a SAMA, may have a small benefit over SABAs in improving health-related quality of life. SAMAs should be discontinued if a LAMA is prescribed. SABAs include salbutamol.

» Regular use of short-acting bronchodilators is not generally recommended. Failure to respond to short-acting bronchodilator may signify an acute exacerbation.

plus supportive care and advice

Treatment recommended for ALL patients in selected patient group

» Smoking cessation should be encouraged in all patients, in addition to guidance on avoiding exposure to occupational or environmental tobacco smoke or other irritants.[1] [2] Smoking
### Management

**Ongoing**

cessation significantly reduces the rate of progression of COPD and risk of malignancies.

- Depending on local guidelines, patients should be vaccinated against influenza virus, *Streptococcus pneumoniae*, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19).[1] [169] Vaccination against influenza is associated with fewer exacerbations of COPD.[170] [171] The US Centers for Disease Control and Prevention (CDC) also recommends the tetanus/diphtheria/pertussis vaccine in people with COPD who were not vaccinated in adolescence, and varicella-zoster virus (shingles) for adults with COPD aged 50 years and over.[169]

- Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control.[144] [145] Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.[147]

- All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. No medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications. Self-management education should include provision of a written action plan. Physical activity is recommended for all patients with COPD.[1]

**Adjunct**

**pulmonary rehabilitation**

Treatment recommended for SOME patients in selected patient group

- Pulmonary rehabilitation compromises aerobic exercise, strength training, and education, and should be started early in the disease course. GOLD guidelines recommend pulmonary rehabilitation for patient groups B to D.[1]

- Pulmonary rehabilitation relieves dyspnoea and fatigue, improves emotional function, and enhances a sense of control to a moderately large and clinically significant extent.[176]

- A large US cohort study found that initiation of pulmonary rehabilitation within 90 days of hospital discharge following an acute
### Ongoing

Exacerbation of COPD was significantly associated with lower mortality risk at 1 year and fewer rehospitalisations at 1 year.[212][180] However, starting pulmonary rehabilitation before hospital discharge could be associated with a higher 12-month mortality, so is not recommended.[181]

**Adjunct oxygen therapy and/or ventilatory support**

Treatment recommended for some patients in selected patient group

- **GOLD guidelines** recommend long-term oxygen therapy in stable patients who have: $\text{PaO}_2 \leq 7.3 \text{ kPa (55 mmHg)}$ or $\text{SaO}_2 \leq 88\%$, with or without hypercapnia confirmed twice over a 3-week period; or $\text{PaO}_2$ between 7.3 kPa (55 mmHg) and 8.0 kPa (60 mmHg) or $\text{SaO}_2$ of 88%, if there is evidence of pulmonary hypertension, peripheral oedema suggesting congestive cardiac failure, or polycythaemia (haematocrit $>$ 55%).[1]

- **Guidelines from the American Thoracic Society (ATS)** recommend prescribing long-term oxygen therapy for at least 15 hours per day in adults with COPD who have severe chronic resting room air hypoxaemia. The ATS defines severe hypoxaemia as either: $\text{PaO}_2 \leq 7.3 \text{ kPa (55 mmHg)}$ or oxygen saturation as measured by pulse oximetry ($\text{SpO}_2$) $\leq 88\%$; or $\text{PaO}_2$ 7.5-7.9 kPa (56-59 mmHg) or $\text{SpO}_2$ of 89% plus one of the following: oedema, haematocrit $\geq 55\%$, or P pulmonale on an ECG.[189]

- **For patients prescribed home oxygen therapy, the ATS recommends** that the patient and their caregivers should receive instruction and training on the use and maintenance of all oxygen equipment and education on oxygen safety, including smoking cessation, fire prevention, and tripping hazards.[189]

- **Supplemental oxygen should be titrated to achieve $\text{SaO}_2 \geq 90\%$.**[1] The patient should be reassessed after 60-90 days to determine whether oxygen is still indicated and is therapeutic.[1] Among different therapeutic modalities in COPD, the only two factors that improve survival are smoking cessation and oxygen supplementation.

- Oxygen therapy helps to minimise pulmonary hypertension by decreasing pulmonary artery pressure, and improves exercise tolerance and quality of life. It has been shown to improve survival.[1][46]
Chronic obstructive pulmonary disease (COPD)

Management

Ongoing

» The ATS suggests prescribing ambulatory oxygen (oxygen delivered during exercise or activities of daily living) in adults with COPD who have severe exertional room air hypoxaemia.[189] However, the ATS suggests not prescribing long-term oxygen therapy in adults with COPD who have moderate chronic resting room air hypoxaemia (SpO₂ of 89%-93%).[189]

» For patients who have COPD and obstructive sleep apnoea, ventilatory support with continuous positive airway pressure (CPAP) can improve survival and reduce hospital admissions.[1] [192] Non-invasive ventilation is occasionally used in patients with very severe but stable COPD, although the optimal timing for initiation and best selection criteria for candidates is unclear.[1] [193] [194]

» Guidelines from the American Thoracic Society suggest the use of nocturnal NIV in addition to usual care for patients with chronic stable hypercapnic COPD.[196] The European Respiratory Society and Canadian Thoracic Society have issued similar guidance.[197] [198]

adjunct roflumilast

Treatment recommended for SOME patients in selected patient group

Primary options

» roflumilast: 500 micrograms orally once daily

» Roflumilast, an oral phosphodiesterase-4 inhibitor, may be prescribed for patients taking LABA/LAMA who have persistent exacerbations and whose blood eosinophils are <100 cells/ microlitre, and for patients taking LABA/LAMA/ICS who have persistent exacerbations.[1]

» Roflumilast should be considered in patients with FEV₁ <50% predicted and chronic bronchitis, particularly if they have had at least one hospitalisation for an exacerbation in the last year.[1]

adjunct azithromycin

Treatment recommended for SOME patients in selected patient group

Primary options

» azithromycin: 250 mg orally once daily; or 500 mg orally three times weekly
Azithromycin may be prescribed for patients taking LABA/LAMA who have persistent exacerbations and whose blood eosinophils are <100 cells/microlitre, and for patients taking LABA/LAMA/ICS who have persistent exacerbations.[1]

Azithromycin increases the risk of colonisation with macrolide-resistant organisms and should not be prescribed for patients with hearing impairment, resting tachycardia, or apparent risk of QTc prolongation.[130] Azithromycin should be considered preferentially, but not only, in former smokers with persistent exacerbations despite appropriate therapy.[1]

Before starting prophylactic antibiotics, baseline ECG and liver function tests should be performed, a sputum sample obtained for culture and sensitivity (including tuberculosis testing), the patient’s sputum clearance technique should be optimised, and bronchiectasis should be excluding with a CT scan.[2][131] ECG and liver tests should be repeated after 1 month of treatment. Prophylactic antibiotic therapy should be reviewed at 6 and 12 months to determine whether there is a benefit in terms of exacerbation rates.[131] If antibiotic therapy is not effective it should be stopped.

adjunct mucolytic

Treatment recommended for SOME patients in selected patient group

Primary options

» erdosteine: consult specialist for guidance on dose

OR

» acetylcysteine: consult specialist for guidance on dose

OR

» carbocisteine: consult specialist for guidance on dose

Patients with the chronic bronchitis phenotype of COPD often produce thick sputum on a frequent basis. Mucolytic agents result in a small reduction in the frequency of acute exacerbations and in days of disability per month, but do not improve lung function or quality of life.[173] One meta-analysis comparing erdosteine, carbocisteine, and
### Ongoing

<table>
<thead>
<tr>
<th>Adjunct</th>
<th>Theophylline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Recommended for SOME patients in selected patient group</td>
</tr>
<tr>
<td>Primary Options</td>
<td></td>
</tr>
<tr>
<td>» theophylline</td>
<td>Consult specialist for guidance on dose</td>
</tr>
<tr>
<td>» Theophylline</td>
<td>(a methylxanthine agent) is not commonly used because of limited potency, narrow therapeutic window, high risk profile, and frequent drug-drug interactions. Theophylline is indicated for persistent symptoms if inhaled therapy is insufficient to relieve airflow obstruction. Theophylline has modest effects on lung function in moderate to severe COPD. [133] A large randomised controlled trial found no effect of oral theophylline alone or with prednisolone on exacerbations of severe COPD. [134] GOLD advise that theophylline should only be used if other long-term bronchodilator treatments are unavailable or unaffordable. [1] Experts may prescribe theophylline after a patient has exhausted all options for inhaled therapies. Toxicity is dose-related.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjunct</th>
<th>Bronchoscopic intervention or surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Recommended for SOME patients in selected patient group</td>
</tr>
<tr>
<td>» Surgical</td>
<td>Interventions (bullectomy, lung volume reduction surgery, [199] [200] and lung transplant) are the last step in the management of COPD. They are used to improve lung dynamics, exercise adherence, and quality</td>
</tr>
</tbody>
</table>
Lung volume reduction surgery is indicated in patients with very severe airflow limitation, and especially in patients with localised upper lobe disease and lower than normal exercise capacity. One meta-analysis found an increased risk of early mortality in patients who underwent lung volume reduction surgery compared to standard care, however, no significant difference was observed in overall mortality. Bullectomy is an option in COPD patients with dyspnoea in whom CT reveals huge bullae occupying at least 30% of the hemithorax. Severely poor functional status and severe decrease in FEV1 (<500 mL) make these options less favourable. Endobronchial valve insertion can produce clinically meaningful improvements in appropriately selected patients with COPD. The procedure may be most beneficial in patients whose dyspnoea is primarily due to hyperinflation and air trapping in the air spaces distal to the terminal bronchioles, which manifests as emphysema with markedly increased residual volume. Contraindications include active lung infection and incomplete lobar fissures (<80%). The most common adverse events associated with endobronchial valve insertion are pneumothorax and exacerbation.

Criteria for referral for lung transplantation include:

- Body mass index, airflow Obstruction, Dyspnoea, and Exercise (BODE) score 5-6 with additional factor(s) present suggestive of increased risk of mortality: frequent acute exacerbations, increase in BODE score >1 over past 24 months, pulmonary artery to aorta diameter >1 on CT scan, and/or FEV1 20% to 25% predicted.

- Clinical deterioration despite maximal treatment including medication, pulmonary rehabilitation, oxygen therapy, and, as appropriate, nocturnal non-invasive positive pressure ventilation.

- Poor quality of life unacceptable to the patient.

- For a patient who is a candidate for bronchoscopic or surgical lung volume reduction (LVR), simultaneous referral for both lung transplant and LVR evaluation is appropriate.

- Lung transplantation has been shown to improve quality of life and functional
Ongoing capacity. However, lung transplantation does not appear to confer a survival benefit. Palliative care

Adjunct palliative care

Treatment recommended for SOME patients in selected patient group

Palliative therapies to improve symptoms of dyspnoea, offer nutritional support, address anxiety and depression, and reduce fatigue may benefit patients with COPD who experience these despite optimal medical therapy. End-of-life care and hospice admission should be considered for patients with very advanced disease. Patient and family should be well educated about the process, and it is suggested that discussions should be held early in the course of the disease before acute respiratory failure develops. Opioid analgesics, fans, neuromuscular electrical stimulation, and chest wall vibration can relieve dyspnoea. One study has suggested that low doses of an opioid analgesic and a benzodiazepine are safe and are not associated with increased hospital admissions or mortality. Another study found that regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD and refractory breathlessness.

One Cochrane review concluded that there is no evidence for or against benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD.

Acupuncture and acupressure may also improve breathlessness and quality of life in patients with advanced COPD.
Emerging

Statins

Statins (HMG-CoA reductase inhibitors) are emerging medications in COPD that have been shown to improve some outcomes, with some improvement in lung function of patients with moderate to severe COPD.[214] Although retrospective studies showed decreased rate and severity of exacerbations, hospitalisation, and mortality in patients using statin therapy, especially in patients with co-existing cardiovascular disease (CVD) or hyperlipidaemia, a prospective study failed to prove this benefit.[215] In a meta-analysis of randomised controlled trials of patients with COPD taking statins, clinical outcomes were better in patients with co-existing CVD, elevated baseline C-reactive protein (CRP), or a high cholesterol level.[216] Further evidence in support of better outcomes in patients with CVD includes a meta-analysis of patients with COPD and comorbid pulmonary hypertension, which revealed improvements in both pulmonary artery pressure and distance walked in 6 minutes following statin therapy.[217] Another meta-analysis compared high-intensity statins with placebo in patients with COPD. Use of statins resulted in a reduction in CRP and interleukin-6, but did not lead to significant difference in exercise capacity or quality of life.[218]

Other medical therapies

The increasing awareness of the role of inflammation in COPD has led to consideration of drugs that attack various targets in the inflammatory cascade. Many broad-spectrum anti-inflammatory drugs are now in phase 3 development for COPD and may enter the COPD market within the next decade. Nitric oxide inhibitors, leukotriene modifiers, and tumour necrosis factor antagonists are among these new treatments.[219] Long-term (≥6 months) treatment with acetylcysteine may decrease exacerbation prevalence but does not appear to affect exacerbation rate, lung volumes, or FEV1.[220] Antiplatelet therapy is associated with decreased all-cause mortality in patients with COPD, independent of cardiovascular risk.[221] Epidermal growth factor receptor kinase has potential to combat mucus overproduction. Therapy to inhibit fibrosis is being developed. There is also a search for serine protease and matrix metalloprotease inhibitors to prevent lung destruction and the subsequent development of emphysema, as well as drugs such as retinoid that may even reverse this process.[222]

Interventional therapies

Target lobe volume reduction, a novel technique for selective bronchoscopic lung volume resection, has now become available. In this technique, a one-way valve is inserted into the hyperinflated and emphysematous segment, leading to the collapse of the non-functional lung segment. Promising reports have been released from case series of patients undergoing this therapy. This approach is an alternative to surgical lung volume reduction in patients with COPD who are likely to require surgery.[223] [224]

Pharmacogenomic therapy

Pharmacogenomic therapy may be important in COPD. It is important to identify the genetic factors that determine why certain heavy smokers develop COPD and others do not. Identification of genes that predispose to the development of COPD may provide novel therapeutic targets.[225] [226]

Club cell protein 16 augmentation

Club cell protein 16 (CC16) is mainly produced by the Club cells (formerly known as Clara cells) in the respiratory tract epithelium. CC16 has anti-inflammatory properties in smoke-exposed lungs, and COPD is associated with CC16 deficiency. Experimental augmentation of CC16 levels reduces inflammation and cellular injury, and so CC16 augmentation may be a new disease-modifying treatment for COPD.[227]

Monoclonal antibodies

Growing evidence implicates eosinophils, a leukocyte usually involved in allergic disease, in the COPD inflammatory cascade.[28] Monoclonal antibody therapy targeting interleukin (IL)-5 or its receptor has proven effective in severe eosinophilic asthma, and may therefore be beneficial in patients with COPD.
Chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. A Cochrane review found that treatment with mepolizumab or benralizumab resulted in a greater reduction in moderate and severe exacerbations than placebo. A subsequent meta-analysis of patient data from the phase 3 COPD mepolizumab clinical trials indicated that patients with higher blood eosinophil counts experienced greater reduction in moderate and severe exacerbations. Phase 3 studies of mepolizumab and benralizumab in COPD are ongoing. Other monoclonal antibodies in clinical development for COPD mostly target acute exacerbations, and include the IL-4 receptor antagonist dupilumab.

**Proton-pump inhibitors**

Best management of COPD exacerbations will likely involve treatment of disease comorbidities. Gastro-oesophageal reflux disease (GORD) is a common comorbidity in patients with COPD; it is associated with pulmonary microaspirations of gastric acid which may induce exacerbations. Proton-pump inhibitors reduce gastric acid secretion and are first-line treatments for GORD. A Cochrane review assessing their efficacy and safety in COPD concluded that the current evidence was insufficient to determine the value of proton-pump inhibitors in this disease.

**Primary prevention**

Avoidance of tobacco exposure (both active and passive measures) and toxic fumes are of invaluable importance in primary prevention of COPD. All smokers should be offered interventions aimed at smoking cessation, including pharmacotherapy and counselling. Although smoking cessation may be associated with minor short-term adverse effects such as weight gain and constipation, its long-term benefits are unquestionable. For disease due to occupational exposures, primary prevention is achieved by elimination or reduction of exposures in the workplace. Public health measures such as congestion charging, high occupancy vehicle lanes, and promoting walking or cycling can be implemented to reduce harm from air pollution.

**Secondary prevention**

Depending on local guidelines, patients should be vaccinated against influenza virus, *Streptococcus pneumoniae*, pertussis (whooping cough), varicella-zoster virus (shingles), and coronavirus disease 2019 (COVID-19). Vitamin D reduces the rate of moderate/severe exacerbations in patients with levels <25 nmol/L. Levels should be checked in patients who are hospitalised with an exacerbation of COPD and supplementation should be given if levels are <25 nmol/L.

Shielding measures (e.g., mask wearing, minimising social contact, and frequent hand washing) could be considered during winter months, alongside established COPD management, to help prevent exacerbations of COPD.

Use of calcium supplementation and other medication may be necessary to prevent or treat osteoporosis in some patients, especially older women on long-term corticosteroid therapy. Bone density scans are done to evaluate progression of this condition.

Physical activity is recommended for all patients with COPD.

**Patient discussions**

All patients should be well educated about the disease course and symptoms of exacerbation or decompensation. Their expectation of the disease, treatment, and prognosis should be realistic. It is important to remember that no medicine has been shown to modify the long-term decline in lung function, and the primary goal of pharmacotherapy is to control symptoms and prevent complications.
One Cochrane review found that self-management interventions that include an action plan for acute exacerbations of COPD are associated with improvements in health-related quality of life and fewer admissions to hospital for respiratory problems. An exploratory analysis found a small, but significantly higher, respiratory-related mortality rate for self-management compared to usual care, although no excess risk of all-cause mortality was seen.[135] Self-management plans should include personalised advice on: breathlessness and stress management techniques, energy conservation, avoiding aggravating factors, how to monitor symptoms, how to manage worsening symptoms, and contact information to use in the event of an exacerbation.[1]

Helping patients to self-manage should ideally address psychosocial concerns and patients’ personal beliefs about COPD and its management. Many patients report losses and limitations on their lifestyle and social interaction after a diagnosis of COPD. It is estimated that patients with COPD are 1.9 times more likely to commit suicide than those without COPD, and symptoms of anxiety, depression, and frustration are common.[137] [138] Studies have found a beneficial effect of cognitive behavioural therapy (CBT) on outcomes including symptoms of depression and anxiety, quality of life, and frequency of emergency department visits.[139] [140] [141] Further research is warranted into the effects of high-resource-intensive versus low-resource-intensive CBT.[141]

One randomised controlled trial found that a telephone health coaching intervention to promote behaviour change in patients with mild COPD in primary care led to improvements in self-management activities, but did not improve health-related quality of life.[142] A meta-analysis found that health coaching that included goal setting, motivational interviewing, and COPD-related health education significantly improved health-related quality of life and reduced hospital admissions for an exacerbation of COPD, but did not decrease all-cause hospital admissions.[143]

Patients should stay as healthy and active as possible. It is necessary to stop active or passive smoking and avoid environmental exposure to toxic fumes.

Regular medical follow-up is necessary to optimise the treatment. If there is any worsening of symptoms, immediate medical attention is required. Patients on continuous oxygen therapy may need an increase in oxygen flow during air travel.

Physical activity is recommended for all patients with COPD and they should be encouraged to maintain it.[1] One systematic review and meta-analysis of randomised controlled trials found that exercise training on its own can improve physical activity in COPD, and greater improvements can be made with the addition of physical activity counselling.[153] Another systematic review and meta-analysis found that a combination of aerobic exercise and strength training was more effective than aerobic exercise alone in increasing leg muscle strength, but there was no difference between the groups in health-related quality of life, walking distance, or exercise capacity.[251] Other studies have demonstrated improvements in peak oxygen uptake, perceived fatigue, and health-related quality of life following adherence to supervised and unsupervised exercise programmes.[155] [156] [157] A Cochrane review found limited evidence for improvement in physical activity with physical activity counselling, exercise training, and pharmacological management of COPD. The authors commented that assessment of quality had been limited by lack of methodological detail and the diverse range of interventions had primarily been assessed in single studies.[158] The optimal timing, components, duration, and models for improving physical activity remain unclear. Meta-analyses suggest that yoga, Qigong, and other home-based breathing exercises can improve exercise capacity and pulmonary function in patients with COPD.[159] [160] [161] Tai Chi has been shown to improve exercise capacity compared to usual care.[162]

Dietary advice and oral supplements have been found to improve body weight, quality of life, respiratory muscle strength and 6-minute walk distance.[163] [164] However, nutritional support has not been consistently found to improve lung function.[164]

Patients who use inhaled therapies should receive training on inhaler device technique. The majority of patients make at least one error in using their inhaler and incorrect inhaler use is associated with worse disease control.[144] [145] Poor technique is more likely when patients are using multiple devices or have never received inhaler technique training.[146] Demonstration of inhaler use by a clinician, device selection, and reviewing technique at subsequent appointments can improve inhaler technique.[147]
Demonstration using a placebo device may be most effective for teaching inhaler technique to adults aged ≥65 years.[148] Patients should be asked to bring their inhalers to clinic to facilitate a review of inhaler use.[1] Pharmacist-led interventions and lay health coaching can improve inhaler technique and adherence in patients with COPD.[149] [150] Inhaler device attributes such as rapid onset of symptom relief and small size have been recorded in patient preference studies.[151] [152]
Monitoring

Patients with COPD should be evaluated on a regular basis depending on the severity of disease. Mild stable COPD patients may be followed up at 6-month intervals, while patients with severe frequent exacerbations, and recently hospitalised patients, need follow-up at 2-week to 1-month intervals. In follow-up sessions, patients should be evaluated to determine adherence to medical regimen, response to therapy, inhaler technique, adverse effects of therapy, and disease progression. The level of dyspnoea at rest and with exercise should be determined, as well as number of exacerbations. Questionnaires such as the COPD Assessment Test (CAT) can be used to assess symptoms. These can be found in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.[1]

Smoking status and smoke exposure should be determined at each appointment, followed by appropriate action.[1]

The GOLD guidelines recommend measuring FEV1 by spirometry at least once a year to identify patients who are declining quickly.[1] Functional capacity should be measured by a timed walking test. Oxygen saturation should be monitored and patients evaluated periodically for the need of supplemental oxygen. Imaging may be indicated if symptoms have worsened; patients with repeated exacerbation characterised by purulent sputum should be investigated for bronchiectasis.[1]

Patients need to be monitored for short-term and long-term complications of COPD and for comorbidities. Patient weight, nutrition status, and physical activity should also be monitored. Cachexia and reduced physical performance are indicators of a poor prognosis.

A Cochrane review found that remote monitoring through telehealth technology reduced the risk of hospital readmission in patients with moderate to severe COPD, and may be considered as an adjunct to usual care.[250]
Complications

<table>
<thead>
<tr>
<th>Complications</th>
<th>Timeframe</th>
<th>Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>cor pulmonale</td>
<td>long term</td>
<td>high</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cor pulmonale is right-sided heart failure secondary to long-standing COPD. It is caused by chronic hypoxia and subsequent vasoconstriction in pulmonary vasculature that causes pulmonary hypertension and right-sided heart failure.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engorged neck veins, a loud P2, lower-extremity oedema, and hepatomegaly are signs of cor pulmonale.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuous oxygen therapy is the mainstay of therapy. Therapy for COPD should be optimised. Judicious use of diuretics is warranted.[245]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lung cancer</td>
<td>long term</td>
<td>medium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD is a risk factor for lung cancer independently of tobacco exposure. A population-based cohort study found that compared with never smokers without COPD, the fully-adjusted hazard ratios for lung cancer in never smokers with COPD, ever smokers without COPD, and ever smokers with COPD were 2.67, 1.97, and 6.19, respectively.[249]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>recurrent pneumonia</td>
<td>variable</td>
<td>high</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent pneumonia is a common complication of COPD and a frequent cause of COPD exacerbation. Either viral or bacterial infections can be the cause.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic lung and airway damage, inflammation, compromised ciliary function, and bacterial colonisation are likely causes of increased vulnerability to infections. Use of inhaled corticosteroids is also associated with increased risk of pneumonia in patients with COPD.[242] [243] [105]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of antibiotic therapy has shown some benefit.[244] Usual treatment time is around 7 to 14 days. Appropriate coverage for <em>Haemophilus influenzae</em> and <em>Streptococcus pneumoniae</em> is mandatory. Pneumococcal vaccination is strongly recommended in patients with COPD.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>depression</td>
<td>variable</td>
<td>high</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression is a common consequence of COPD. It is estimated that patients with COPD are 1.9 times more likely to commit suicide than those without COPD.[137] If any mood change occurs, a psychiatric evaluation may be necessary.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pneumothorax</td>
<td>variable</td>
<td>medium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occurs because of lung parenchyma damage with sub-pleural bulla formation and rupture. Spontaneous pneumothorax is very common with chronic severe cough or chest trauma, and may be life-threatening.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High levels of suspicion are necessary for prompt diagnosis. CXR or chest CT confirms the diagnosis.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chronic obstructive pulmonary disease (COPD)

Follow up

<table>
<thead>
<tr>
<th>Complications</th>
<th>Timeframe</th>
<th>Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chest CT: severe COPD changes with right pneumothorax</strong>&lt;br&gt;From the collection of Manoochehr Abadian Sharifabad, MD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conservative management may be sufficient in minor cases. In severe cases, chest tube insertion is necessary to prevent tension pneumothorax and haemodynamic instability. If recurrent pneumothorax occurs, then surgical interventions, such as video-assisted thoracoscopy pleurodesis or bullectomy, are warranted.

**respiratory failure**<br>variable<br>medium

A study of a large number of patients with COPD and acute respiratory failure reported in-hospital mortality of 17% to 49%. [241] Therapy includes non-invasive positive pressure ventilation and/or mechanical ventilation.

**anaemia**<br>variable<br>medium

Anaemia is more prevalent than previously thought, affecting almost 25% of patients with COPD. [246] A low haematocrit indicates a poor prognosis in patients receiving long-term oxygen treatment. [247] One meta-analysis found that patients with comorbid anaemia were also more likely to spend longer
Chronic obstructive pulmonary disease (COPD)

<table>
<thead>
<tr>
<th>Complications</th>
<th>Timeframe</th>
<th>Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>periods of time in hospital than those without comorbid anaemia, as well as experiencing higher rates of mortality.[248]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**polycythaemia**

Secondary polycythaemia can develop in the presence of arterial hypoxaemia, especially in continuing smokers. It can be identified by haematocrit >55%. Many times these patients require supplemental home oxygen.

---

**Prognosis**

COPD is a disease with an indeterminate course and variable prognosis. Its prognosis depends on several factors including genetic predisposition, environmental exposures, comorbidities, and, to a lesser degree, acute exacerbations.

Although short-term survival for patients with COPD and respiratory failure depends on the overall severity of acute illness, long-term survival is primarily influenced by the severity of COPD and the presence of comorbid conditions. Traditionally, prognosis has been reported based on the FEV1, which is a part of pulmonary function testing. A meta-regression analysis showed a significant correlation between increased FEV1 and lower risk of COPD exacerbation.\[233\]

In addition to the FEV1, other factors that predict prognosis are weight (very low weight is a negative prognostic factor, with one meta-analysis identifying a significant association between low body mass index and accelerated FEV1 decline), distance walked in 6 minutes, and degree of shortness of breath with activities.\[234\] [235] These factors, known as the Body mass index, airflow Obstruction, Dyspnoea, and Exercise (BODE) index, can be used to provide information on prognosis for 1-year, 2-year, and 4-year survival.\[236\] One study revealed that plasma pro-adrenomedullin concentration plus BODE index is a better prognostic tool than BODE index alone.\[237\] Elevation of adrenomedullin, arginine vasopressin, atrial natriuretic peptide, and C-reactive protein\[238\] is associated with increased risk of death in patients with stable COPD.\[239\] UK guidelines do not recommend using the BODE index to assess prognosis.\[2\]

Recently, more interest has been put on comorbidities and prior exacerbations as the predictor of COPD course. CODEX index (comorbidities, obstruction, dyspnoea, and previous severe exacerbations) is proved to be superior to BODE index in predicting prognosis for patients with COPD.\[240\] Frequent COPD exacerbations and requirement for multiple intubation and invasive mechanical ventilation for acute respiratory failure in patients with COPD are markers of poor prognosis.\[241\]

Among different therapeutic modalities in COPD, the only two factors that improve survival are smoking cessation and oxygen supplementation.
# Diagnostic guidelines

## United Kingdom

**Chronic obstructive pulmonary disease in over 16s: diagnosis and management** ([https://www.nice.org.uk/guidance/ng115](https://www.nice.org.uk/guidance/ng115))  
*Published by: National Institute for Health and Care Excellence*  
*Last published: 2019*

## Europe

*Published by: Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)*  
*Last published: 2020*

*Published by: Romanian Society of Pneumology (SRP)*  
*Last published: 2020*

## International

**Global strategy for the diagnosis, management, and prevention of COPD** ([https://goldcopd.org/2022-gold-reports-2](https://goldcopd.org/2022-gold-reports-2))  
*Published by: Global Initiative for Chronic Obstructive Lung Disease*  
*Last published: 2021*

# Treatment guidelines

## United Kingdom

*Published by: British Thoracic Society*  
*Last published: 2020*

**Chronic obstructive pulmonary disease in over 16s: diagnosis and management** ([https://www.nice.org.uk/guidance/ng115](https://www.nice.org.uk/guidance/ng115))  
*Published by: National Institute for Health and Care Excellence*  
*Last published: 2019*

**Managing malnutrition in COPD** ([https://www.malnutritionpathway.co.uk/copd](https://www.malnutritionpathway.co.uk/copd))  
*Published by: Managing Adult Malnutrition*  
*Last published: 2020*
## Europe

**Endoscopic lung volume reduction: an expert panel recommendation**
  
  **Published by:** Swiss Respiratory Society; European Association for Bronchology and Interventional Pulmonology  
  **Last published:** 2019

**Withdrawal of inhaled corticosteroids in COPD** ([https://www.ersnet.org/guidelines](https://www.ersnet.org/guidelines))
  
  **Published by:** European Respiratory Society  
  **Last published:** 2020

  
  **Published by:** Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)  
  **Last published:** 2020

**Guidelines on long-term home non-invasive ventilation for management of COPD** ([https://www.ersnet.org/guidelines/](https://www.ersnet.org/guidelines/))
  
  **Published by:** European Respiratory Society  
  **Last published:** 2019

  
  **Published by:** Romanian Society of Pneumology (SRP)  
  **Last published:** 2020

## International

**Global strategy for the diagnosis, management, and prevention of COPD** ([https://goldcopd.org/2022-gold-reports-2](https://goldcopd.org/2022-gold-reports-2))
  
  **Published by:** Global Initiative for Chronic Obstructive Lung Disease  
  **Last published:** 2021

**Enhancing implementation, use, and delivery of pulmonary rehabilitation** ([https://www.thoracic.org/statements/pulmonary-rehab.php](https://www.thoracic.org/statements/pulmonary-rehab.php))
  
  **Published by:** American Thoracic Society; European Respiratory Society  
  **Last published:** 2015

  
  **Published by:** American Thoracic Society; European Respiratory Society  
  **Last published:** 2014
# North America

**Pharmacologic management of chronic obstructive pulmonary disease**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>American Thoracic Society</th>
<th>Last published: 2020</th>
</tr>
</thead>
</table>

**Home oxygen therapy for adults with chronic lung disease**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>American Thoracic Society</th>
<th>Last published: 2020</th>
</tr>
</thead>
</table>

**Clinical practice guideline on pharmacotherapy in patients with COPD - 2019 update of evidence**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>Canadian Thoracic Society</th>
<th>Last published: 2019</th>
</tr>
</thead>
</table>

**Pulmonary rehabilitation exercise prescription in chronic obstructive pulmonary disease: review of selected guidelines**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>American Association of Cardiovascular and Pulmonary Rehabilitation</th>
<th>Last published: 2016</th>
</tr>
</thead>
</table>

**Chronic obstructive pulmonary disease: a 2019 evidence analysis center evidence-based practice guideline**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>Academy of Nutrition and Dietetics</th>
<th>Last published: 2021</th>
</tr>
</thead>
</table>

**Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>American Thoracic Society</th>
<th>Last published: 2020</th>
</tr>
</thead>
</table>

**Management of chronic obstructive pulmonary disease (COPD)**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>US Department of Veterans Affairs/Department of Defense</th>
<th>Last published: 2021</th>
</tr>
</thead>
</table>

**Long-term non-invasive ventilation in patients with chronic obstructive pulmonary disease (COPD): 2021 Canadian Thoracic Society Clinical practice guideline update**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>Canadian Thoracic Society</th>
<th>Last published: 2021</th>
</tr>
</thead>
</table>

**Defining modern pulmonary rehabilitation. An official American Thoracic Society workshop report**

<table>
<thead>
<tr>
<th>Published by:</th>
<th>American Thoracic Society</th>
<th>Last published: 2021</th>
</tr>
</thead>
</table>
### Asia

*Published by:* Asian Pacific Society of Respirology  
*Last published:* 2019

*Published by:* Expert panel  
*Last published:* 2020

### Oceania

**COPD-X Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease** ([https://copdx.org.au](https://copdx.org.au))  
*Published by:* Lung Foundation Australia; Thoracic Society of Australia and New Zealand  
*Last published:* 2021

*Published by:* Lung Foundation Australia; Thoracic Society of Australia and New Zealand  
*Last published:* 2017

*Published by:* Exercise & Sports Science Australia (ESSA)  
*Last published:* 2021
Online resources


Evidence tables

How does umeclidinium compare with placebo for people with chronic obstructive pulmonary disease (COPD)?

This table is a summary of the analysis reported in a Cochrane Clinical Answer that focuses on the above important clinical question.

View the full source Cochrane Clinical Answer (https://www.cochranelibrary.com/cca/doi/10.1002/cca.1829/full)

Evidence A

Confidence in the evidence is high or moderate to high where GRADE has been performed and the intervention is more effective/beneficial than the comparison for key outcomes.

Population: Adults with moderate-to-severe COPD
Intervention: Umeclidinium (once daily via a dry powder inhaler for 12-52 weeks)
Comparison: Placebo

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Effectiveness (BMJ rating)†</th>
<th>Confidence in evidence (GRADE)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants with exacerbations requiring corticosteroids, antibiotics, or both at 52 weeks</td>
<td>Favours intervention</td>
<td>High</td>
</tr>
<tr>
<td>Quality of life at 24-52 weeks (measured by the St George's Respiratory Questionnaire [SGRQ])</td>
<td>Favours intervention</td>
<td>Moderate</td>
</tr>
<tr>
<td>Number of participants with hospital admissions due to COPD exacerbation at 52 weeks (measured by the Transitional Dyspnoea Index [TDI])</td>
<td>No statistically significant difference</td>
<td>Low</td>
</tr>
<tr>
<td>Improvement in symptoms at 24 weeks</td>
<td>Favours intervention</td>
<td>High</td>
</tr>
<tr>
<td>Lung function at 4-52 weeks</td>
<td>Favours intervention</td>
<td>High</td>
</tr>
<tr>
<td>Non-fatal serious adverse events</td>
<td>No statistically significant difference</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
### Evidence tables

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Effectiveness (BMJ rating)†</th>
<th>Confidence in evidence (GRADE)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events</td>
<td>No statistically significant difference</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

* Evidence levels

The Evidence level is an internal rating applied by BMJ Best Practice. See the [EBM Toolkit](https://bestpractice.bmj.com/info/evidence-tables/) for details.

**Confidence in evidence**

A - High or moderate to high  
B - Moderate or low to moderate  
C - Very low or low  

† Effectiveness (BMJ rating)

Based on statistical significance, which demonstrates that the results are unlikely to be due to chance, but which does not necessarily translate to a clinical significance.

‡ Grade certainty ratings

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>The authors are very confident that the true effect is similar to the estimated effect.</td>
</tr>
<tr>
<td>Moderate</td>
<td>The authors are moderately confident that the true effect is likely to be close to the estimated effect.</td>
</tr>
<tr>
<td>Low</td>
<td>The authors have limited confidence in the effect estimate and the true effect may be substantially different.</td>
</tr>
<tr>
<td>Very Low</td>
<td>The authors have very little confidence in the effect estimate and the true effect is likely to be substantially different.</td>
</tr>
</tbody>
</table>

[BMJ Best Practice EBM Toolkit: What is GRADE?](https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/)
Key articles


References


Chronic obstructive pulmonary disease (COPD)


<table>
<thead>
<tr>
<th>Reference Number</th>
<th>Reference Details</th>
</tr>
</thead>
</table>


Full text (https://www.doi.org/10.1136/bmjopen-2019-036455)  


Full text (https://www.doi.org/10.1002/14651858.CD002309.pub6)  


Full text (https://www.doi.org/10.1016/S2213-2600(14)70019-0)  

Full text (https://www.doi.org/10.1002/14651858.CD013198.pub2)  

Full text (https://www.doi.org/10.1002/14651858.CD009764.pub3)  


Figure 1: COPD chest x-ray (AP view): hyperinflated lung, flattened diaphragm, increased intercostal spaces

From the collection of Manoochehr Abadian Sharifabad, MD
Chronic obstructive pulmonary disease (COPD)

Figure 2: COPD chest x-ray (lateral view): hyperinflated lung, flattened diaphragm, increased antero-posterior diameter (barrel chest) in lateral view

From the collection of Manoochehr Abadian Sharifabad, MD
**Figure 3: COPD chest CT: hyperinflated lung, emphysematous changes, and increased antero-posterior diameter (barrel chest)**

*From the collection of Manoochehr Abadian Sharifabad, MD*
**Figure 4: Initial pharmacological management of COPD**

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report); used with permission

- **Group C**
  - ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization
  - LAMA
  - mMRC 0-1, CAT < 10

- **Group A**
  - 0 or 1 moderate exacerbations (not leading to hospital admission)
  - A bronchodilator
  - mMRC 0-1, CAT < 10

- **Group D**
  - LAMA or LAMA + LABA* or ICS + LABA**
  - mMRC ≥ 2, CAT ≥ 10

- **Group B**
  - A long acting bronchodilator (LABA or LAMA)
  - mMRC ≥ 2, CAT ≥ 10

---

**Notes:**

- *Consider if highly symptomatic (e.g. CAT > 20)
- **Consider if blood eosinophil count in cells per microliter ≥ 300

**Abbreviations:**

- mMRC: modified Medical Research Council dyspnea questionnaire
- CAT: COPD Assessment Test™
- LABA: long-acting beta-2 agonist
- LAMA: long-acting muscarinic antagonist
- ICS: inhaled corticosteroid
Chronic obstructive pulmonary disease (COPD)

Follow-up pharmacological treatment

If response to initial treatment is appropriate, maintain it
If not:
- Consider the predominant treatable trait to target (dyspnea or exacerbations)
  Use exacerbation pathway if both exacerbations and dyspnea need to be targeted
- Place patient in box corresponding to current treatment & follow indications
- Assess response, adjust and review
- These recommendations do not depend on the ABCD assessment at diagnosis

Dyspnea

LABA or LAMA

LABA + LAMA

LABA + ICS

- Consider switching inhaler device or molecules
- Investigate (and treat) other causes of dyspnea

Exacerbations

LABA or LAMA

LABA + LAMA

LABA + ICS

LABA + LAMA + ICS

Roflimast
FEV₁ < 50% & chronic bronchitis

Azithromycin

Consider if eos ≥ 100

In former smokers

Consider if eos < 100

*Consider if eos ≥ 300 or eos ≥ 100 AND ≥ 2 moderate exacerbations / 1 hospitalization

**Consider de-escalation of ICS or switch if pneumonia, inappropriate original indication or lack of response to ICS

eos: blood eosinophil count in cells per microliter
LABA: long-acting beta-2 agonist
LAMA: long-acting muscarinic antagonist
ICS: inhaled corticosteroid
FEV₁: forced expiratory volume in 1 second

Figure 5: Escalation therapy for patients with COPD

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report). Reproduced with permission
Figure 6: Chest CT: severe COPD changes with right pneumothorax

From the collection of Manoochehr Abadian Sharifabad, MD
Disclaimer

BMJ Best Practice is intended for licensed medical professionals. BMJ Publishing Group Ltd (BMJ) does not advocate or endorse the use of any drug or therapy contained within this publication nor does it diagnose patients. As a medical professional you retain full responsibility for the care and treatment of your patients and you should use your own clinical judgement and expertise when using this product.

This content is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition, since such standards and practices in medicine change as new data become available, you should consult a variety of sources. We strongly recommend that you independently verify specified diagnosis, treatments and follow-up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the drug to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region.

Information included in BMJ Best Practice is provided on an “as is” basis without any representations, conditions or warranties that it is accurate and up to date. BMJ and its licensors and licensees assume no responsibility for any aspect of treatment administered to any patients with the aid of this information. To the fullest extent permitted by law, BMJ and its licensors and licensees shall not incur any liability, including without limitation, liability for damages, arising from the content. All conditions, warranties and other terms which might otherwise be implied by the law including, without limitation, the warranties of satisfactory quality, fitness for a particular purpose, use of reasonable care and skill and non-infringement of proprietary rights are excluded.

Where BMJ Best Practice has been translated into a language other than English, BMJ does not warrant the accuracy and reliability of the translations or the content provided by third parties (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages). BMJ is not responsible for any errors and omissions arising from translation and adaptation or otherwise. Where BMJ Best Practice lists drug names, it does so by recommended International Nonproprietary Names (rINNs) only. It is possible that certain drug formularies might refer to the same drugs using different names.

Please note that recommended formulations and doses may differ between drug databases drug names and brands, drug formularies, or locations. A local drug formulary should always be consulted for full prescribing information.

Treatment recommendations in BMJ Best Practice are specific to patient groups. Care is advised when selecting the integrated drug formulary as some treatment recommendations are for adults only, and external links to a paediatric formulary do not necessarily advocate use in children (and vice-versa). Always check that you have selected the correct drug formulary for your patient.

Where your version of BMJ Best Practice does not integrate with a local drug formulary, you should consult a local pharmaceutical database for comprehensive drug information including contraindications, drug interactions, and alternative dosing before prescribing.

Interpretation of numbers

Regardless of the language in which the content is displayed, numerals are displayed according to the original English-language numerical separator standard. For example 4 digit numbers shall not include a comma nor a decimal point; numbers of 5 or more digits shall include commas; and numbers stated to be less than 1 shall be depicted using decimal points. See Figure 1 below for an explanatory table.

BMJ accepts no responsibility for misinterpretation of numbers which comply with this stated numerical separator standard.

This approach is in line with the guidance of the International Bureau of Weights and Measures Service.

Figure 1 – BMJ Best Practice Numeral Style
Contributors:

// Authors:

Manoochehr Abadian Sharifabad, MD
Fountain Valley Regional Medical Center
Fountain Valley, CA
DISCLOSURES: MAS declares that he has no competing interests.

// Acknowledgements:

Dr Manoochehr Abadian Sharifabad would like to gratefully acknowledge Dr Jonathan P. Parsons and Dr Michael Ezzie, the previous contributors to this topic. JPP has contributed at speakers’ bureaus for GlaxoSmithKline, Inc., Schering-Plough, Inc., and AstraZeneca, Inc.
DISCLOSURES: ME declares that he has no competing interests.

// Peer Reviewers:

Hormoz Ashtyani, MD, FCCP
Hackensack University Medical Center
Hackensack, NJ
DISCLOSURES: HA declares that he has no competing interests.

William Janssen, MD
Assistant Professor of Medicine
National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver, CO
DISCLOSURES: WJ declares that he has no competing interests.

Francis Thien, MD, FRACP, FCCP
Associate Professor
Director of Respiratory Medicine, Eastern Health & Monash University, Victoria, Australia
DISCLOSURES: FT declares that he has no competing interests.